Compositions and methods for disruption of bacterial biofilms without associated inflammation - Patents.com
The modified high mobility group-box 1 domain (mHMGB1) with specific cysteine substitutions targets and disrupts bacterial biofilms, addressing antibiotic resistance and inflammation issues, providing a safer and more effective biofilm treatment.
Patent Information
- Application Number
- JP2019550715
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-03-15
- Filing Date
- 2018-03-14
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2038-03-14
AI Technical Summary
Bacterial biofilms pose significant challenges due to their resistance to antibiotics and immune system access, leading to chronic infections and the emergence of antibiotic-resistant strains, with existing treatments causing inflammation and secondary infections.
A modified high mobility group-box 1 domain (mHMGB1) with cysteine-to-serine substitutions (C23S, C45S, and/or C106S) is used to disrupt bacterial biofilms by inhibiting DNABII protein binding to microbial DNA, reducing inflammation and bacterial load without inducing strong immune responses.
mHMGB1 effectively disrupts biofilms in vitro and in vivo, reducing bacterial burden and preventing biofilm formation, while minimizing inflammatory responses, thus offering a safer and more effective treatment for biofilm-mediated infections.
Smart Images

Figure 0007596069000105 
Figure 0007596069000106 
Figure 0007596069000107
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 471,834, filed March 15, 2017, the contents of which are hereby incorporated by reference in their entirety. background
[0002] Bacteria that persist in biofilms in the human body are responsible for approximately 2 / 3 of all chronic / recurrent diseases. These biofilms are often composed of bacteria that are protected from gaining access to the bacteria inside the biofilm by an outer "slime" that is composed primarily of DNA, antibiotics and other antibacterial agents that thwart the innate and adaptive immune systems. Biofilms make it extremely difficult to clear the infection from the body. Additionally, biofilms can act as a reservoir for acute infections, often with fatal outcomes.
[0003] At least one protein from the DNABII protein family is found in all known eubacteria and is naturally found outside the bacterial cell. While these proteins induce a strong innate immune response, the host subject is unable to naturally generate specific antibodies against family members as a result of infection. A major challenge with bacterial biofilms is the inability of the host immune system and / or antibiotics and / or other antimicrobials to gain access to the bacteria protected within the biofilm.
[0004] Biofilms are also present in industrial settings. For example, biofilms affect a wide range of petroleum process challenges from production sites to gas station storage tanks. In the field, sulfate-reducing biofilm bacteria produce hydrogen sulfide (sour oil). In process pipelines, biofilm activity generates slime that clogs filters and openings. Biofilms and biofilm organisms also cause corrosion of pipelines and petroleum process equipment. These challenges can manifest throughout oil or gas production facilities to the point where adherent and corrosive biofilm organisms have even been found on the surfaces of end product storage tanks.
[0005] In the home, biofilms are found in or on any surface that supports microbial growth, such as in water pipes, on food preparation surfaces, in toilets, and in swimming pools and spas.
[0006] Biofilms affect a wide range of water treatment (both domestic and industrial). They can grow on the surfaces of treatment equipment and impede the performance of the equipment (e.g., reduced heat transfer or plugging of filters and membranes). Biofilms growing on cooling tower fill can add enough weight to cause the fill to collapse. Biofilms cause corrosion even of highly specialized stainless steels. Biofilms in water treatment can reduce the value of the end product. Biofilms growing in potable water distribution systems can potentially harbor pathogenic organisms, decay organisms or bacteria that reduce the aesthetic quality of the water.
[0007] Thus, a need exists for disrupting the protective barrier of biofilms to treat or kill associated bacterial infections and clear them from surfaces and water systems. The present invention fulfills this need and also provides related advantages. Summary of the Invention [Means for solving the problem]
[0008] Abstract HMGB1 (eukyotic protein) was discovered 40 years ago as a non-histone chromatin protein (Goodwin et al. 1973). HMGB1 is a ubiquitously expressed nuclear protein that functions as a component in the full range of nuclear protein interactions, including DNA replication, repair and gene regulation, through its ability to bind DNA. It also promotes protein-protein interactions in various cancers, autophagy (Tang et al. 2011) and the non-canonical secretory pathway (Lee et al. 2010). Although HMGB1 is primarily present in the nucleus, it can be secreted and / or released into the extracellular space by several cell types, including activated immune cells (macrophages, monocytes, neutrophils, dendritic cells and natural killer cells), epithelial cells and fibroblasts (Yang et al. 2007). Extracellular HMGB1 exhibits cytokine-inducing, chemokine-like, and proangiogenic functions (Melloni et al. 1995a; 1995b; Pistoia and Raffaghello 2011) (Ranzato et al. 2009) (Abraham et al. 2000; Agnello et al. 2002) (Mardente et al. 2012) (Wang et al. 1999). It is also involved in bacterial killing (Gong et al. 2009; Zetterstrom et al. 2006), and cellular senescence (Davalos et al. 2013). HMGB1 associates with neutrophil extracellular traps (NETs), which are released by neutrophils to fight microbial infections.
[0009] Antibiotics are the first choice for the treatment of bacterial infections. Biofilms are a necessary component for approximately 80% of all bacterial infections and strongly influence the chronic and recurrent nature of infectious diseases. Also, bacteria in biofilms are up to 1000 times more resistant to antibiotics. The chronic and recurrent nature of biofilm-mediated bacterial infections requires the excessive use of antibiotics, which in turn has led to the sobering emergence of bacteria resistant to numerous antibiotics. This perplexing collateral damage as a result of the excessive use of antibiotics results in failure of antibiotic therapy and difficulty / inability to treat infections. Also, a significant side effect of antibiotics is the negative impact on commensal microbiota that can result in secondary infections.
[0010] HMGB1 has two tandem DNA-binding domains (A and B boxes) and a highly acidic C-terminal tail. HMGB1 functions as a monomer and uses its two tandem DNA-binding domains to bind into the DNA minor groove and bend DNA. HMGB1 also has a C-terminal domain consisting of approximately 30 acidic amino acid residues that has antimicrobial activity against planktonic bacteria (Gong et al. 2009). Applicants have previously shown that DNABII proteins, which bind and bend DNA, are essential for the structure of biofilms formed by a number of human pathogens (Brandstetter et al. 2013; Brockson et al. 2014; Devaraj et al. 2015; Freire et al. 2016; Goodman et al. 2011; Gustave et al. 2013; Idicula et al. 2016; Justice et al. 2012; Novotny et al. 2013a; Novotny et al. 2016; Rocco et al. 2016). HMGB1 does not share sequence or structural homology with DNABII proteins, but has been shown to replace them in vitro for several bacterial functions (Paull et al. 1993; Segall et al. 1994). Applicants have shown that while DNABII proteins stabilize the eDNA-dependent extracellular matrix of biofilms, recombinant HMGB1 (rHMGB1) disrupts preformed bacterial biofilms in vitro (Table 1), clears NTHI biofilms from the chinchilla middle ear in an experimental model of otitis media (OM) (Figures 1A-1B), and inhibits Burkholderia cenocepacia biofilm development in the mouse respiratory tract, directly resulting in reduced bacterial load (Figures 2A-2D).
[0011] Although rHMGB1 has been shown to be effective in disrupting biofilms in vitro and in vivo, it has also been extensively shown to induce strong inflammatory responses that could potentially be harmful to the host. Several post-translational modifications (PTMs) including acetylation, phosphorylation, methylation, glycosylation, ADP-ribosylation, and oxidation of cysteine residues have been described for HMGB1 to regulate its location (nuclear, cytoplasmic, or extracellular), function, and ability to bind DNA (reviewed in Kang et al. 2014). Human HMGB1 contains three cysteine residues at positions 23, 45, and 106, and oxidation of these cysteine residues affects its inflammatory properties (Kazama et al. 2008). HMGB1 containing a C106 thiol group and a C23-C45 disulfide bond triggers inflammation, while terminally oxidized cysteines promote inflammation resolution (Yang et al. 2012).
[0012] Aspects disclosed herein relate to a modified high mobility group-box 1 domain comprising one or more or all of the substitutions selected from the group of C23S, C45S, and C106S, an isolated or recombinant polynucleotide encoding the modified high mobility group-box 1 domain, a vector comprising the isolated or recombinant polynucleotide, and a composition comprising an effective amount of the modified high mobility group-box 1 domain and / or the isolated or recombinant polynucleotide and / or the vector. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S.
[0013] Applicants show herein that C45S recombinant HMGB1 or modified HMGB1(C45S) ("mHMGB1(C45S)") has been shown to disrupt existing biofilms both in vitro and in vivo (in two mammalian models). Dispersing large amounts of bacteria from a biofilm to a planktonic state in vivo may have potential drawbacks in that these now planktonic bacteria may gain access to other sites that they did not have access to before resulting in potential second site infection. This dispersal effect may also result in sepsis. None of these outcomes have been observed with mHMGB1, and there are means to circumvent these potential limitations in addition to the fact that these potential pitfalls may be moot depending on the site of biofilm infection.
[0014] A further aspect relates to a method for inhibiting, competing or titrating the binding of deoxyribonucleic acid B II (DNABII) polypeptide to microbial DNA in a biofilm, comprising, or alternatively consisting essentially of, or even consisting of, contacting the microbial DNA in the biofilm with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S and C106S, or any one or more of the compositions disclosed above, thereby inhibiting, competing or titrating the binding of the DNABII polypeptide to the microbial DNA. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises one or more or all of the substitutions C23S, C45S and C106S. In some embodiments, the contacting is in vitro or in vivo. In some embodiments, the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), Aggregatibacter actinomycetemcomitans. In some embodiments, the method further comprises, or alternatively consists essentially of, or even further consists of administering to a subject in need thereof an effective amount of an antibiotic to the surface, optionally with a coating.
[0015] Yet another aspect relates to a method for preventing the formation of biofilm on a surface, comprising contacting the surface with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S, or any one or more of the compositions disclosed above, optionally with coating, thereby inhibiting, competing, or titrating the binding of DNABII polypeptide to microbial DNA during biofilm formation. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C23S, C45S, and C106S. In some embodiments, the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), Aggregatibacter actinomycetemcomitans. In some embodiments, the method further comprises, or alternatively consists essentially of, or even further consists of the step of administering, and optionally coating, an effective amount of an antibiotic to the surface.
[0016] Further aspects relate to a method for preventing or treating microbial infection in a subject that produces biofilm, comprising administering an effective amount of any one or more of the isolated or recombinant polypeptides comprising modified high mobility group-box 1 domains comprising one or more substitutions selected from the group of C23S, C45S and C106S or compositions disclosed above, thereby inhibiting, competing or titrating the binding of DNABII polypeptide to microbial DNA, or alternatively consisting essentially of, or even consisting of. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the modifications C23S, C45S and C106S. In some embodiments, the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), Aggregatibacter actinomycetemcomitans. In some embodiments, the method further comprises, or alternatively consists essentially of, or even further consists of administering an effective amount of an antibiotic.
[0017] It is recognized that among the equivalents to the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S of modified high mobility group box 1. For modified high mobility group-box 2, the corresponding cysteine residues are found at positions 23, 45, and 106; for modified high mobility group-box 3, the corresponding cysteine residues are found at positions 23, 45, and 104; and for modified high mobility group-box 4, the corresponding cysteine residues are found at positions 45, 104, 164, and 178. Accordingly, the Applicant believes that the above-mentioned aspects disclosed with respect to modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S are equally applicable to the above-mentioned high mobility group-box species having one or more cysteine to serine substitutions at the referred positions (e.g. modified high mobility group-box 2 containing one or more substitutions selected from the group of C23S, C45S, and C106S; modified high mobility group-box 3 containing one or more substitutions selected from the group of C23S, C45S, and C104S; and modified high mobility group-box 4 containing one or more substitutions selected from the group of C45S, C104S, C164S, and C178S). In certain embodiments, for example, the following items are provided: (Item 1) A modified high mobility group-box 1 domain comprising one or more substitutions selected from the group consisting of C23S, C45S, and C106S. (Item 2) 2. The modified high mobility group-box 1 domain described in item 1, wherein the modified high mobility group-box 1 domain comprises the substitution C45S. (Item 3) 2. The modified high mobility group-box 1 domain of item 1, wherein the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S. (Item 4) An isolated or recombinant polynucleotide encoding the modified high mobility group-box 1 domain according to any one of items 1 to 3. (Item 5) A vector comprising the isolated or recombinant polynucleotide according to item 4. (Item 6) A composition comprising an effective amount of a modified high mobility group-box 1 domain described in any one of items 1 to 3 and / or an isolated polynucleotide or recombinant polynucleotide described in item 4 and / or a vector described in item 5. (Item 7) A method for inhibiting, competing or titrating binding of a deoxyribonucleic acid B II (DNABII) polypeptide to microbial DNA in a biofilm, the method comprising contacting the microbial DNA in the biofilm with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S, thereby inhibiting, competing or titrating binding of the DNABII polypeptide to the microbial DNA. (Item 8) 8. The method of claim 7, wherein the modified high mobility group-box 1 domain comprises the substitution C45S. (Item 9) 8. The method of claim 7, wherein the modified high mobility group-box 1 domain contains the substitutions C23S, C45S, and C106S. (Item 10) 10. The method according to any one of items 7 to 9, wherein the contacting step is in vitro or in vivo. (Item 11) 11. The method according to any one of items 7 to 10, wherein the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), or Aggregatibacter actinomycetemcomitans. (Item 12) 12. The method according to any one of items 7 to 11, further comprising the step of administering an effective amount of an antibiotic to the surface, optionally with a coating. (Item 13) A method for preventing the formation of a biofilm on a surface, the method comprising contacting the surface with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain containing one or more substitutions selected from the group of C23S, C45S, and C106S, optionally coated, thereby inhibiting, competing or titrating binding of a DNABII polypeptide to microbial DNA exuded during biofilm formation. (Item 14) 14. The method of claim 13, wherein the modified high mobility group-box 1 domain comprises the substitution C45S. (Item 15) 14. The method of claim 13, wherein the modified high mobility group-box 1 domain contains the substitutions C23S, C45S, and C106S. (Item 16) 16. The method according to any one of items 13 to 15, wherein the contacting step is in vitro or in vivo. (Item 17) 17. The method according to any one of items 13 to 16, wherein the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), Aggregatibacter actinomycetemcomitans. (Item 18) 18. The method according to any one of items 13 to 17, further comprising administering to said surface, optionally with a coating, an effective amount of an antibiotic. (Item 19) A method for preventing or treating a microbial infection in a biofilm-producing subject, the method comprising administering an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain containing one or more substitutions selected from the group of C23S, C45S, and C106S, thereby inhibiting, competing or titrating binding of a DNABII polypeptide to microbial DNA. (Item 20) 20. The method of claim 19, wherein the modified high mobility group-box 1 domain comprises the substitution C45S. (Item 21) 20. The method of claim 19, wherein the modified high mobility group-box 1 domain contains the substitutions C23S, C45S, and C106S. (Item 22) 22. The method according to any one of items 19 to 21, wherein the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), Aggregatibacter actinomycetemcomitans. (Item 23) 23. The method according to any one of items 19 to 22, further comprising the step of administering, optionally coating, an effective amount of an antibiotic to said surface. [Brief description of the drawings]
[0018] [Figure 1] Figures 1A-1B show that rHMGB1 and mHMGB1(C45S) promote bacterial clearance in an established experimental OM animal model. Diluent, 5 μg rHMGB1, or 5 μg mHMGB1(C45S) were delivered directly into the middle ear of chinchillas 4 and 5 days after infection with NTHI. Animals were sacrificed 24 hours later and their middle ears were imaged (Figure 1A) and blindly scored (Figure 1B) based on the criteria described below Figure 1A. Bars represent SEM. ***P<0.001. Images and scoring show that HMGB1 was able to clear preformed NTHI biofilms in vivo.
[0019] [Figure 2-1] Figures 2A-2D show that mHMGB1(C45S) promotes bacterial clearance and does not increase inflammatory responses in the airways of mice infected with B. cenocepacia. C57BL / 6 mice were infected with 107 CFU(it) and given rHMGB1 or mHMGB1(C45S) at the same time. After 18 h (Figure 2A) B. cenocepacia CFU were quantified in BAL, (Figure 2B) total host cells infiltrating into the lungs were counted in BAL, and (Figure 2C) BAL cells were stained with anti-CD45, CD11b, and Ly-6G to measure neutrophil migration. Bars represent standard deviation. *P<0.05; **P<0.005. (Figure 2D) Lungs were collected at 72 hpi. Tissues were fixed, embedded in paraffin, sectioned, and stained with H&E. All panels show 10x magnification. Note that mHMGB1(C45S) treatment resulted in a significant reduction in B. cenocepacia CFU and inflammatory cell infiltration in vivo compared to rHMGB1. [Figure 2-2]Figures 2A-2D show that mHMGB1(C45S) promotes bacterial clearance and does not increase inflammatory responses in the airways of mice infected with B. cenocepacia. C57BL / 6 mice were infected with 107 CFU(it) and given rHMGB1 or mHMGB1(C45S) at the same time. After 18 h (Figure 2A) B. cenocepacia CFU were quantified in BAL, (Figure 2B) total host cells infiltrating into the lungs were counted in BAL, and (Figure 2C) BAL cells were stained with anti-CD45, CD11b, and Ly-6G to measure neutrophil migration. Bars represent standard deviation. *P<0.05; **P<0.005. (Figure 2D) Lungs were collected at 72 hpi. Tissues were fixed, embedded in paraffin, sectioned, and stained with H&E. All panels show 10x magnification. Note that mHMGB1(C45S) treatment resulted in a significant reduction in B. cenocepacia CFU and inflammatory cell infiltration in vivo compared to rHMGB1.
[0020] [Diagram 3] FIG. 3 shows that mHMGB1(C45S) does not promote neutrophil migration in the peritoneal cavity. C57BL / 6 mice were injected into the peritoneal cavity with 4% thioglycollate, rHMGB1, or mHMGB1(C45S). Cells in the peritoneal exudates were stained with anti-CD45, CD11b, and Ly-6G to determine the total neutrophil numbers in the peritoneal cavity (PC). Bars represent SEM. *P<0.05. Note that mHMGB1(C45S) lacks the proinflammatory activity of rHMGB1.
[0021] [Figure 4]Figure 4 shows the anti-biofilm effect of HMGB1 variants against bacterial pathogens. The indicated HMGB1 isoforms (200 nM) were added to each in vitro formed bacterial biofilm for 24 hours. 16 hours after inoculation, the biofilms were stained with LIVE / DEAD® and then visualized via CLSM. Images were analyzed by Comstat to calculate the average thickness and biomass. Representative images of UPEC are shown in (Figure 4A). The percentage change in average thickness compared to the control is shown in (Figure 4C). 800 nM rHMGB1 and 200 nM mHMGB1(C45S) were used for S. aureus (ESKAPE) biofilm treatment. 800 nM rHMGB1 and mHMGB1(C45S) were used for E. faecium (ESKAPE) biofilm treatment. These were incubated with the respective proteins for 1 hour as opposed to 16 hours. Biomass (not shown) showed the same trend. Bars represent SEM. Statistical significance compared to control was assessed by unpaired t-test (*P<0.05). HMGB1 and its variants were able to significantly disrupt established biofilms.
[0022] [Figure 5-1] Figure 5 shows that mHMGB1(C45S) enhances antibiotic-mediated killing. B.cenocepacia biofilms were preformed for 24 hours and then incubated with minocycline (1 mg / ml), mHMGB1(C45S)(200 nM), or mHMGB1(C45S)(200 nM)+minocycline (1 mg / ml) for 16 hours. Biofilms were stained with LIVE / DEAD® and imaged via CLSM. Live cells are shown in the top half of each image and dead cells are shown in the bottom half of each image. Note that dead cells are increased only in the presence of both mHMGB1(C45S) and minocycline. [Figure 5-2]Figure 5 shows that mHMGB1(C45S) enhances antibiotic-mediated killing. B.cenocepacia biofilms were preformed for 24 hours and then incubated with minocycline (1 mg / ml), mHMGB1(C45S)(200 nM), or mHMGB1(C45S)(200 nM)+minocycline (1 mg / ml) for 16 hours. Biofilms were stained with LIVE / DEAD® and imaged via CLSM. Live cells are shown in the top half of each image and dead cells are shown in the bottom half of each image. Note that dead cells are increased only in the presence of both mHMGB1(C45S) and minocycline.
[0023] [Figure 6] Figure 6 shows that rHMGB1 and mHMGB1(C45S) promote biofilm dissolution in an experimental OM animal model. Diluent or 5 μg rHMGB1 or mHMGB1(C45S) was delivered directly into the middle ear of chinchillas 4 and 5 days after infection with NTHI. Animals were sacrificed 24 hours later and their middle ears were imaged (Figure 6A) and blindly scored (Figure 6B) based on the criteria described below (Figure 6A). Bars represent SEM. ***P<0.001. Images and scoring show that HMGB1 promoted the clearance of pre-formed NTHI biofilms in vivo.
[0024] [Figure 7]FIG. 7 shows that mHMGB1(C45S) promotes bacterial clearance but does not increase airway inflammation in mice infected with B. cenocepacia. C57BL / 6 mice were infected with 107 CFU(it) and simultaneously received 5 mg rHMGB1 or mHMGB1(C45S). (FIG. 7A) B. cenocepacia aggregates were visible by fluorescence microscopy in sections probed with α-B. cenocepacia antibody. After 18 h, (FIG. 7B) CFU were quantified in the BAL, and (FIG. 7C) BAL cells were stained with α-CD45, CD11b, and Ly-6G to measure neutrophil migration. Bars represent SD. *P<0.05. (FIG. 7D) Lung tissues collected at 72 hpi were fixed, embedded in paraffin, sectioned, and stained with H&E. 10× magnification. Treatment with mHMGB1(C45S) resulted in a significant reduction in B. cenocepacia CFU and inflammatory cell infiltration in vivo compared to rHMGB1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] Detailed Description definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Although any materials and methods similar or equivalent to those described herein can be used in the practice or testing of this invention, the preferred methods, devices and materials are described herein. All technical publications and patent publications cited herein are incorporated by reference in their entirety. Nothing herein should be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior art. For example, see Molecular Cloning: A Laboratory Manual, 4th edition, edited by Green and Sambrook (2012); Current Protocols in Molecular Biology, series, edited by Ausubel et al. (2015); Methods in Enzymology, series (Academic Press, Inc., NY); PCR 1: A Practical Approach, series, edited by MacPherson et al. (2015); PCR 2: A Practical Approach, series, edited by MacPherson et al. (1995); PCR: The Basics, series, edited by McPherson et al. (2006); Antibodies, A Laboratory Manual, edited by Harlow and Lane (1999); Antibodies, A Laboratory Manual, edited by Greenfield (2014); Culture of Animal Cells: A Manual of Basic Technique, 6th edition, edited by Gait (1984); U.S. Patent No. 4,683,195; and Hames and Higgins (1984). Nucleic Acid Hybridization; Anderson (1999) Nucleic Acid Hybridization;Edited by Herdewijn (2005) Oligonucleotide Synthesis: Methods and Applications; Edited by Hames and Higgins (1984) Transcription and Translation; Edited by Buzdin and Lukyanov (2007) Nucleic Acids Hybridization: Modern Applications; Immobilized Cells and Enzymes (IRL Press (1986)); Edited by Grandi (2007) In Vitro Transcription and Translation Protocols, 2nd edition; edited by Guisan (2006) Immobilization of Enzymes and Cells; Perbal (1988) A Practical Guide to Molecular Cloning, 2nd edition; edited by Miller and Calos (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); edited by Makrides (2003) Gene Transfer and Expression in Mammalian Cells; edited by Mayer and Walker (1987) Immunochemistry Methods in Cell and Molecular Biology (Academic Press, London); Lundblad and Macdonald, eds. (2010) Handbook of Biochemistry and Molecular Biology, 4th Edition; and Herzenberg et al., eds. (1996) Weir's Handbook of Experimental Immunology, 5th Edition; and the most recent editions of each of these available at the time of filing.
[0026] All numerical designations (e.g., pH, temperature, time, concentration, and molecular weight (including ranges)) are approximations that vary (+) or (-) by increments of 1.0 or 0.1, where appropriate, or alternatively by ±15%, or alternatively 10%, or alternatively 5%, or alternatively 2%. It is to be understood, although not always expressly stated, that all numerical designations are preceded by the term "about." It is also to be understood, although not always expressly stated, that the reagents described herein are exemplary only and that equivalents of such are known in the art.
[0027] As used in the specification and claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a polypeptide" includes a plurality of polypeptides, including mixtures thereof.
[0028] As used herein, the term "comprising" is intended to mean that the compositions and methods include the recited elements, but do not exclude others. "Consisting essentially of" when used to define compositions and methods shall mean excluding any other elements of essential importance to the combination for its intended use. Thus, a composition consisting essentially of elements as defined herein does not exclude trace contaminants from isolation and purification methods and pharma- ceutically acceptable carriers (e.g., phosphate buffered saline, preservatives, etc.). "Consisting of" shall mean excluding more than trace elements and substantial method steps of other components for administering the compositions of the invention. Embodiments defined by each of these transitional phrases are within the scope of the invention.
[0029] By "biofilm" is intended a thin layer or organized community of microorganisms, together with the polymers (e.g., DNA) they secrete and / or release, that can sometimes adhere to the surface of a structure, which can be organic or inorganic. The biofilms are highly resistant to microbiotics and antimicrobial agents. They reside on gum tissue, teeth, and restorations, causing caries and periodontal disease (also known as periodontal plaque disease). They also cause chronic middle ear infections. Biofilms can also form on the surfaces of dental implants, stents, catheter lines, and contact lenses. They can grow on pacemakers, heart valve replacements, artificial joints, and other surgical implants. The Centers for Disease Control and Prevention estimates that more than 65% of nosocomial (hospital-acquired) infections are caused by biofilms. Fungal biofilms also frequently contaminate medical devices. They cause chronic vaginal infections and lead to life-threatening systemic infections in people with compromised immune systems. Biofilms are also involved in many diseases. For example, cystic fibrosis patients have Pseudomonas infections that often result in antibiotic-resistant biofilms.
[0030] By "DNABII polypeptide or protein" is intended a DNA-binding protein or polypeptide that is composed of a DNA-binding domain and thus has a specific or general affinity for DNA. In one aspect, they bind to DNA in the minor groove. Non-limiting examples of DNABII proteins are the integration host factor (IHF) protein and the histone-like protein (HU) from E. coli strain U93. Other DNA-binding proteins that may be associated with biofilms include DPS (Genbank Accession No.: CAA49169), H-NS (Genbank Accession No.: CAA47740), Hfq (Genbank Accession No.: ACE63256), CbpA (Genbank Accession No.: BAA03950) and CbpB (Genbank Accession No.: NP_418813).
[0031] "Integration host factor" or "IHF" proteins are bacterial proteins used by bacteriophages to integrate their DNA into host bacteria. They are DNA-binding proteins that function in genetic recombination and in transcriptional and translational regulation. They also bind to extracellular microbial DNA. The genes encoding the IHF protein subunits in E. coli are the himA gene (Genbank accession number: POA6X7.1) and himD (POA6Y1.1) gene.
[0032] "HU" or "histone-like protein from E. coli strain U93" refers to a class of heterodimeric proteins typically associated with E. coli. HU proteins are known to bind to DNA junctions. Related proteins have been isolated from other microorganisms. The complete amino acid sequence of E. coli HU was reported by Laine et al. (1980) Eur. J. Biochem. 103(3):447-481. Antibodies against the HU protein are commercially available from Abcam.
[0033] By "microbial DNA" is intended single- or double-stranded DNA derived from biofilm-producing microorganisms.
[0034] "Inhibiting, preventing or breaking down" a biofilm contemplates either a prophylactic or therapeutic reduction in the structure of the biofilm. In one aspect, the terms "inhibiting, competing or titrating" contemplate the reduction in the formation of the DNA / protein matrix that is a component of a microbial biofilm (e.g., as shown in FIG. 1).
[0035] By "bent polynucleotide" is intended a double-stranded polynucleotide that contains a small loop on one strand that does not pair with the other strand and any polynucleotide that is bent end-to-end beyond the natural thermal fluctuation, i.e., beyond the 150 bp persistence length for native B-form double-stranded DNA. In some embodiments, the loop is 1 base to about 20 bases in length, or alternatively 2 bases to about 15 bases in length, or alternatively about 3 bases to about 12 bases in length, or alternatively about 4 bases to about 10 bases in length, or alternatively has about 4, 5, or 6, or 7, or 8, or 9, or 10 bases.
[0036] A "subject" of diagnosis or treatment is a cell or an animal (e.g., a mammal or a human). Non-human animals that are diagnosed or treated include those that are subject to infection or animal models (e.g., monkeys, murines (e.g., rats, mice), chinchillas, canines (e.g., dogs), leporids (e.g., rabbits), farm animals, sport animals, and pets.
[0037] The terms "protein", "peptide" and "polypeptide" are used interchangeably and in their broadest sense refer to a compound of two or more subunit amino acids, amino acid analogs or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunits may be linked by other bonds (e.g., esters, ethers, etc.). A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that may make up the sequence of a protein or peptide. As used herein, the term "amino acid" may refer to any natural and / or unnatural or synthetic amino acid (including glycine and both D and L optical isomers, amino acid analogs and peptidomimetics). The 20 amino acids naturally found in the human body are shown in the following table with their respective three-letter abbreviations, one-letter abbreviations, structures, and corresponding codons: [Table A-1] [Table A-2]
[0038] The terms "polynucleotide" and "oligonucleotide" are used interchangeably and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. A polynucleotide may have any three-dimensional structure and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: genes or gene fragments (e.g., probes, primers, EST or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, RNAi, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A polynucleotide may contain modified nucleotides (e.g., methylated nucleotides and nucleotide analogs). If present, modifications to the nucleotide structure may be imparted before or after assembly of the polynucleotide. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotide can be further modified after polymerization (e.g., by conjugation with a labeling component). The term also refers to both double-stranded and single-stranded molecules.Unless otherwise specified or required, any embodiment of the present invention that is a polynucleotide includes both double-stranded form and each of the two complementary single-stranded forms that are known or predicted to constitute that double-stranded form.
[0039] The terms "isolated" or "recombinant" as used herein with respect to nucleic acids (e.g., DNA or RNA) refer to molecules that are separated from other DNA or RNA present in the natural source of the macromolecule and polypeptide, respectively. The term "isolated or recombinant nucleic acid" is meant to include nucleic acid fragments that are not naturally occurring as fragments and would not be found in the natural state. The term "isolated" is also used herein to refer to polynucleotides, polypeptides and proteins that are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides. In other embodiments, the terms "isolated or recombinant" refer to cells, tissues, polynucleotides, peptides, polypeptides, proteins, antibodies or fragments thereof that are separated from components, cells and others with which they are normally associated in nature. For example, an isolated cell is a cell that is separated from tissues or cells of dissimilar phenotypes or genotypes. An isolated polynucleotide is separated from the 3' and 5' contiguous nucleotides with which it is normally associated in its native or natural environment, e.g., on a chromosome. As will be apparent to one of skill in the art, non-naturally occurring polynucleotides, peptides, polypeptides, proteins, antibodies or fragments thereof do not require "isolation" to distinguish them from their naturally occurring counterparts.
[0040] The terms "equivalent" or "biological equivalent" are used interchangeably when referring to specific molecular, biological or cellular substances and are intended to have minimal homology while still maintaining a desired structure or functionality.
[0041] Unless expressly stated and unless otherwise intended, it should be presumed that when the present invention relates to a polypeptide, protein, polynucleotide, or antibody, equivalents or biological equivalents of such are intended to be within the scope of the present invention. As used herein, the term "biolgically equivalent thereof" is intended to be synonymous with "equivalent thereof" when referring to a reference protein, antibody, polypeptide, or nucleic acid, and is intended to have minimal homology while still maintaining a desired structure or functionality. Unless specifically stated herein, any polynucleotide, polypeptide, or protein referred to herein is also intended to include its equivalent. For example, an equivalent is intended to have at least about 70% homology or identity, or alternatively about 80% homology or identity, and alternatively at least about 85%, or alternatively at least about 90%, or alternatively at least about 95%, or alternatively 98% homology or identity, and exhibits substantially equivalent biological activity to the reference protein, polypeptide, or nucleic acid. In another aspect, the term contemplates a polynucleotide that hybridizes under high stringency conditions to a reference polynucleotide or its complement.
[0042] A polynucleotide or polynucleotide region (or polypeptide or polypeptide region) having a certain percentage (e.g., 80%, 85%, 90% or 95%) of "sequence identity" to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same when comparing the two sequences. The alignment and percent homology or sequence identity can be determined using software programs known in the art, such as those described in Current Protocols in Molecular Biology (Ausubel et al., eds., 1987), Supplement 30, Section 7.7.18, Table 7.7.1. Preferably, default parameters are used for the alignment. A preferred alignment program is BLAST, using default parameters. Particularly preferred programs are BLASTN and BLASTP using the following default parameters: genetic code=standard; filter=none; strand=both; cutoff=60; expectation=10; matrix=BLOSUM62; description=50 sequences; sort by=HIGH SCORE; database=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translation+SwissProtein+SPupdate+PIR. Details of these programs can be found at the following internet address: ncbi.nlm.nih.gov / cgi-bin / BLAST.
[0043] "Homology" or "identity" or "similarity" refers to sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing a position in each sequence that can be aligned for comparison purposes. If a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or "non-homologous" sequence shares less than 30% identity, or alternatively less than 25% identity, less than 20% identity, or alternatively less than 10% identity with one of the sequences of the present invention.
[0044] "Homology" or "identity" or "similarity" can also refer to two nucleic acid molecules that hybridize under stringent conditions to a reference polynucleotide, or its complement.
[0045] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex stabilized through hydrogen bonds between the bases of the nucleotide residues. The hydrogen bonds can occur by Watson-Crick base pairing, Hoogsteen binding, or in any other sequence-specific manner. The complex can include two strands forming a duplex structure, three or more strands forming a multistranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction can constitute a step in a more extensive process, such as the initiation of a PCR reaction or the enzymatic cleavage of a polynucleotide by a ribosome.
[0046] Examples of stringent hybridization conditions include the following: incubation temperature is about 25°C to about 37°C; hybridization buffer concentration is about 6xSSC to about 10xSSC; formamide concentration is about 0% to about 25%; and wash solution is about 4xSSC to about 8xSSC. Examples of moderate hybridization conditions include the following: incubation temperature is about 40°C to about 50°C; buffer concentration is about 9xSSC to about 2xSSC; formamide concentration is about 30% to about 50%; and wash solution is about 5xSSC to about 2xSSC. Examples of high stringency conditions include the following: incubation temperature is about 55°C to about 68°C; buffer concentration is about 1xSSC to about 0.1xSSC; formamide concentration is about 55% to about 75%; and wash solution is about 1xSSC, 0.1xSSC, or deionized water. Generally, hybridization incubation times are 5 minutes to 24 hours, with one, two or more washing steps, and washing incubation times are about 1 minute, 2 minutes, or 15 minutes. SSC is a 0.15M NaCl and 15mM citrate buffer. It is understood that equivalents of SSC using other buffer systems can be used.
[0047] The term "encode" as applied to a polynucleotide refers to a polynucleotide that is said to "encode" a polypeptide when it is transcribed and / or translated to produce an mRNA for the polypeptide and / or fragment thereof, either in its native state or when manipulated by methods well known to those of skill in the art. The antisense strand is the complement of such a nucleic acid, and the coding sequence can be derived therefrom.
[0048] As used herein, the terms "treating," "treatment," and the like refer to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic, in that it completely or partially prevents a disorder or its signs or symptoms, and / or it may be therapeutic, in that it partially or completely cures a disorder and / or adverse effects attributable to the disorder.
[0049] By "prevent" is intended to prevent the disorder or effect in vitro or in vivo in a system or subject susceptible to the disorder or effect. An example of such would be preventing the formation of a biofilm in a system infected with a microorganism known to form a biofilm.
[0050] "Pharmaceutically acceptable carrier" refers to any diluent, excipient or carrier that can be used in the composition of the present invention. Pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., phosphate, glycine, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acids), water, salts or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate), polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference textbook in this field. They are preferably selected for the intended form of administration, ie, oral tablets, capsules, elixirs, syrups, etc., and are consistent with conventional pharmaceutical practice.
[0051] "Administration" can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods for determining the most effective means and dosages are known to those of skill in the art and vary with the composition used for treatment, the therapeutic purpose, the target cell being treated, and the subject being treated. Single or multiple administrations can be performed with the dosage level and pattern selected by the treating physician. Appropriate dosage formulations and methods for administering agents are known in the art. The route of administration can also be determined, and methods for determining the most effective route of administration are known to those of skill in the art and vary with the composition used for treatment, the therapeutic purpose, the health or disease stage of the subject being treated, and the target cell or tissue. Non-limiting examples of routes of administration include oral administration, nasal administration, injection, and topical application.
[0052] The term "effective amount" refers to an amount sufficient to achieve a beneficial or desired result or effect. In the context of therapeutic or prophylactic applications, the effective amount depends on the type and severity of the condition in question, as well as the characteristics of the individual subject (e.g., general health, age, sex, weight, and tolerance to the pharmaceutical composition). In the context of an immunogenic composition, in some embodiments, the effective amount is an amount sufficient to generate a protective response against a pathogen. In other embodiments, the effective amount of the immunogenic composition is an amount sufficient to generate antibody production against an antigen. In some embodiments, the effective amount is the amount required to confer passive immunity to a subject in need. With respect to an immunogenic composition, in some embodiments, the effective amount depends on the intended use, the degree of immunogenicity of the particular antigenic compound, and the health / responsiveness of the subject's immune system, in addition to the factors mentioned above. Those skilled in the art can determine the appropriate amount depending on these and other factors.
[0053] In the case of in vitro application, in some embodiments, the effective amount depends on the size and nature of the application in question. It also depends on the nature and sensitivity of the in vitro target and the method in use. Those skilled in the art can determine the effective amount based on these and other considerations. The effective amount may include one or more administrations of the composition, depending on the embodiment.
[0054] The agents and compositions may be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures (eg, active ingredients in a pharmaceutical composition).
[0055] The agents of the present invention may be administered for therapy by any suitable route of administration, it being recognized that the preferred route will vary with the condition and composition of the recipient, as well as the disease being treated.
[0056] Examples of solid supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylase, natural and modified cellulose, polyacrylamide, gabbro, and magnetite. The nature of the carrier can be either soluble or insoluble to some extent. The support material can have virtually any conceivable structural configuration, so long as the coupled molecule can bind to a polynucleotide, polypeptide, or antibody. Thus, the configuration of the support can be spherical, as in a bead, or cylindrical, as in the inner surface of a test tube or the outer surface of a rod. Alternatively, the surface can be flat, such as a sheet or test strip, or alternatively a polystyrene bead. Those skilled in the art will know many other suitable carriers for binding antibodies or antigens, or can ascertain the same using routine experimentation.
[0057] As used herein, the terms "antibody", "antibodies" and "immunoglobulin" include whole antibodies and any antigen-binding fragments or single chains thereof. Thus, the term "antibody" includes any protein or peptide-containing molecule that contains at least a portion of an immunoglobulin molecule. The terms "antibody", "antibodies" and "immunoglobulin" also include any isotype of immunoglobulin, antibody fragment that retains specific binding to an antigen, including, but not limited to, Fab, Fab', F(ab)2, Fv, scFv, dsFv, Fd fragments, dAb, VH, VL, VhH, and V-NAR domains; minibodies, diabodies, triabodies, tetrabodies and kappa bodies; multispecific antibody fragments formed from antibody fragments and one or more isolated. Examples of such include, but are not limited to, a heavy or light chain complementarity determining region (CDR) or a ligand binding portion thereof, a heavy or light chain variable region, a heavy or light chain constant region, a framework (FR) region, or any portion thereof, at least a portion of a binding protein, a chimeric antibody, a humanized antibody, a single chain antibody, and a fusion protein comprising an antigen-binding portion of an antibody and a non-antibody protein. The variable regions of the heavy and light chains of the immunoglobulin molecule contain the binding domains that interact with the antigen. The constant region of the antibody (Ab) may mediate the binding of the immunoglobulin to host tissue. The term "anti-" when used before a protein name, e.g., anti-IHF, anti-HU, anti-OMP P5, refers to a monoclonal or polyclonal antibody that binds to and / or has affinity for a particular protein. For example, "anti-IHF" refers to an antibody that binds to the IHF protein. The specific antibody may have affinity for or bind to a protein other than the protein to which the antibody was raised.For example, anti-IHF is specifically raised against the IHF protein, but may also bind to other proteins related either through sequence homology or through structural homology.
[0058] The antibody may be a polyclonal antibody, a monoclonal antibody, a multispecific antibody (e.g., a bispecific antibody), and an antibody fragment, so long as it exhibits the desired biological activity. The antibody may be isolated from any suitable biological source (e.g., mouse, rat, sheep, and canine).
[0059] As used herein, a "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population. Monoclonal antibodies are highly specific because each monoclonal antibody is directed against a single determinant on an antigen. The antibody may be detectably labeled, for example, with a radioisotope, an enzyme that produces a detectable product, a fluorescent protein, and the like. The antibody may be further conjugated to other moieties, such as members of a specific binding pair, such as, for example, biotin (a member of the biotin-avidin specific binding pair), and the like. The antibody may also be bound to a solid support, including, but not limited to, a polystyrene plate or beads.
[0060] Monoclonal antibodies can be produced using hybridoma technology or recombinant DNA methods known in the art. Hybridomas are cells produced in the laboratory from the fusion of antibody-producing lymphocytes and non-antibody-producing cancer cells (usually myelomas or lymphomas). The hybridomas grow and produce continuous samples of specific monoclonal antibodies. Alternative techniques for producing or selecting antibodies include in vitro exposure of lymphocytes to the antigen of interest and screening antibody display libraries in cells, phage, or similar systems.
[0061] The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies disclosed herein may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species (e.g., mouse) have been grafted onto human framework sequences. Thus, as used herein, the term "human antibody" refers to an antibody in which substantially all portions of the protein (e.g., CDRs, framework, CDRs ... L , C H Domain (e.g., C H1 , C H2 , C H3 The term refers to an antibody in which the amino acid sequence (VL, VH) of the nucleotide sequence (SEQ ID NO: 1), the hinge (VL, VH)) is substantially non-immunogenic in humans, with only minor sequence changes or variations. Similarly, antibodies of primates (monkeys, baboons, chimpanzees, etc.), rodents (mouse, rats, rabbits, guinea pigs, hamsters, etc.) and other mammals refer to antibodies specific to such species, subgenus, genus, subfamily, family. Furthermore, chimeric antibodies include any combination of the above. Such changes or variations retain or reduce the immunogenicity in humans or other species relative to unmodified antibodies, as appropriate. Thus, a human antibody is different from a chimeric antibody or a humanized antibody. It is noted that a human antibody can be produced by a non-human animal or a prokaryotic or eukaryotic cell that can express functionally rearranged human immunoglobulin (e.g., heavy and / or light chain) genes. Furthermore, when a human antibody is a single-chain antibody, it can include a linker peptide not found in a native human antibody. For example, an Fv can include a linker peptide (e.g., from 2 to about 8 glycine or other amino acid residues) connecting the variable region of the heavy chain and the variable region of the light chain. Such a linker peptide is considered to be of human origin.
[0062] As used herein, a human antibody is "derived from" a particular germline sequence if the antibody is obtained from a system that uses human immunoglobulin sequences, for example, by immunizing a transgenic mouse with human immunoglobulin genes or by screening a human immunoglobulin gene library. A human antibody "derived from" a human germline immunoglobulin sequence can thus be identified by comparing the amino acid sequence of the human antibody to the amino acid sequence of a human germline immunoglobulin. The selected human antibody is typically at least 90% identical in amino acid sequence to the amino acid sequence encoded by the human germline immunoglobulin gene and contains amino acid residues that identify the human antibody as human when compared to the germline immunoglobulin amino acid sequence of another species (e.g., mouse germline sequence). In certain cases, a human antibody can be at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. Typically, a human antibody derived from a particular human germline sequence will display no more than 10 amino acid differences from the amino acid sequence encoded by the human germline immunoglobulin gene, In certain cases, the human antibody may display no more than 5, or even no more than 4, 3, 2, or 1 amino acid differences from the amino acid sequence encoded by the germline immunoglobulin gene.
[0063] "Human monoclonal antibody" refers to antibodies displaying a single binding specificity which have variable and constant regions derived from human germline immunoglobulin sequences. The term also contemplates recombinant human antibodies. Methods for making these antibodies are described herein.
[0064] The term "recombinant human antibody," as used herein, includes all human antibodies prepared, expressed, generated or isolated by recombinant means (e.g., antibodies isolated from animals (e.g., mice) that are transgenic or transchromosomal for human immunoglobulin genes or hybridomas prepared therefrom, antibodies isolated from host cells that have been transformed to express the antibodies, e.g., from transfectomas, antibodies isolated from recombinant, combinatorial human antibody libraries, and antibodies prepared, expressed, generated or isolated by any other means involving splicing of human immunoglobulin gene sequences to other DNA sequences). Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies may be subjected to in vitro mutagenesis (or, when animals transgenic for human Ig sequences are used, in vivo somatic mutagenesis) such that the amino acid sequences of the VH and VL regions of the recombinant antibodies, while derived from and related to human germline VH and VL sequences, are sequences that may not naturally exist within the human antibody germline repertoire in vivo. Methods for making these antibodies are described herein.
[0065] As used herein, a chimeric antibody is an antibody whose light and heavy chain genes have been constructed, typically by genetic engineering, from antibody variable and constant region genes belonging to different species.
[0066] As used herein, the term "humanized antibody" or "humanized immunoglobulin" refers to a human / non-human chimeric antibody that contains minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from the variable region of the recipient are replaced by residues from the variable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and capacity. Humanized antibodies may contain residues that are not found in either the recipient antibody or the donor antibody. The humanized antibody may also optionally contain at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin, a non-human antibody that contains one or more amino acids in the framework region, constant region, or CDRs replaced with correspondingly positioned amino acids from a human antibody. In general, humanized antibodies are expected to generate a reduced immune response in a human host when compared to a non-humanized version of the same antibody. The humanized antibody may have conservative amino acid substitutions that have substantially no effect on antigen binding or other antibody functions. Conservative substitution groupings include: glycine-alanine, valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, serine-threonine, and asparagine-glutamine.
[0067] The terms "polyclonal antibody" or "polyclonal antibody composition" as used herein refer to a preparation of antibodies derived from different B-cell lines. They are a mixture of immunoglobulin molecules secreted against a particular antigen, each recognizing a different epitope.
[0068] As used herein, the term "antibody derivative" includes full length antibodies or fragments of antibodies in which one or more of the amino acids have been chemically modified, such as by alkylation, pegylation, acylation, ester formation or amide formation, for example, to link the antibody to a second molecule. This includes, but is not limited to, pegylated antibodies, cysteine pegylated antibodies, and variants thereof.
[0069] As used herein, the term "label" refers to a directly or indirectly detectable compound or composition (e.g., an N-terminal histidine tag (N-His), a magnetically active isotope (e.g., 115 Sn, 117 Sn and 119 Sn), non-radioactive isotopes (e.g. 13 C and 15The term also includes sequences conjugated to a polynucleotide that provide a signal upon expression of the inserted sequence (e.g., green fluorescent protein (GFP) and the like). The term "label" generally contemplates a composition that is covalently attached to the composition to be detected, while it specifically excludes naturally occurring nucleotides and amino acids that are known to fluoresce under certain conditions (e.g., temperature, pH, etc.), and generally any natural fluorescence that may be present in the composition to be detected. The label may be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzyme label, may catalyze a chemical alteration of a substrate compound or composition that is detectable. The label may be suitable for small-scale detection or may be more suitable for high-throughput screening. Thus, suitable labels include, but are not limited to, magnetically active isotopes, non-radioactive isotopes, radioisotopes, fluorescent dyes, chemiluminescent compounds, dyes, and proteins (including enzymes). The label may be simply detected or quantified. A merely detected response generally includes a response whose presence is merely confirmed, whereas a quantified response generally includes a response that has a quantifiable (e.g., reportable as a number) value (e.g., intensity, polarization, and / or other property). In luminescent or fluorescent assays, the detectable response may be generated directly using a luminophore or fluorophore associated with the assay component that actually participates in the binding, or indirectly using a luminophore or fluorophore associated with another (e.g., reporter or indicator) component. Examples of luminescent labels that generate a signal include, but are not limited to, bioluminescence and chemiluminescence. A detectable luminescent response generally includes a change in a luminescent signal or the generation of a luminescent signal. Suitable methods of luminescent labeling assay components and luminophores are known in the art and are described, for example, in Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6th Edition).Examples of luminescent probes include, but are not limited to, aequorin and luciferase.
[0070] As used herein, the term "immunoconjugate" includes an antibody or antibody derivative associated or linked to a second agent (e.g., a cytotoxic agent, a detectable agent, a radioactive agent, a targeting agent, a human antibody, a humanized antibody, a chimeric antibody, a synthetic antibody, a semi-synthetic antibody, or a multispecific antibody).
[0071] Examples of suitable fluorescent labels include fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methyl-coumarin, pyrene, malachite green, stilbene, Lucifer Yellow, and Cascade Blue. TM Other suitable optical dyes include, but are not limited to, Fluorescent Probes and Texas Red. Other suitable optical dyes are described in Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6th ed.).
[0072] In another aspect, the fluorescent label is functionalized to facilitate covalent attachment to cellular components present on or at the surface of cells or tissues (e.g., cell surface markers).Suitable functional groups include, but are not limited to, isothiocyanate groups, amino groups, haloacetyl groups, maleimides, succinimidyl esters, and sulfonyl halides, all of which can be used to attach the fluorescent label to a second molecule.The choice of functional group of the fluorescent label depends on the site of attachment to either a linker, drug, marker, or second labeling drug.
[0073] "Eukaryotic cell" includes all of the kingdoms of life except Monera. They can be easily distinguished through their membrane-bound nuclei. Animals, plants, fungi, and protozoa are eukaryotic organisms or organisms whose cells are organized into complex structures by internal membranes and cytoskeleton. The most characteristic membrane-bound structure is the nucleus. Unless specifically stated, the term "host" includes eukaryotic hosts, including, for example, yeast, higher plant, insect, and mammalian cells. Non-limiting examples of eukaryotic cells or hosts include monkeys, cows, pigs, mice, rats, birds, reptiles, and humans.
[0074] "Prokaryotic cells", which usually lack a nucleus or any other membrane-bound organelles, are divided into two regions, bacteria and archaea. In addition to chromosomal DNA, these cells may also contain genetic information in circular loops called episomes. Bacterial cells are very small, roughly the size of an animal mitochondrion (about 1-2 μm in diameter and 10 μm in length). Prokaryotic cells are characterized by three main shapes: rod-shaped, spherical, and spiral. Instead of undergoing an elaborate replication process like eukaryotes, bacterial cells divide by binary fission. Examples include, but are not limited to, Bacillus bacteria, E. coli bacteria, and Salmonella bacteria.
[0075] A "native" or "natural" antigen is a polypeptide, protein, or epitope-containing fragment that has been isolated from a natural biological source and is capable of specifically binding to an antigen receptor, in particular a T cell antigen receptor (TCR), in a subject.
[0076] The terms "antigen" and "antigenic" refer to a molecule that has the ability to be recognized by an antibody or other acting as a member of an antibody-ligand pair. "Specific binding" refers to the interaction of an antigen with the variable regions of immunoglobulin heavy and light chains. Antibody-antigen binding can occur in vivo or in vitro. Those skilled in the art will appreciate that macromolecules, including proteins, nucleic acids, fatty acids, lipids, lipopolysaccharides and polysaccharides, have the potential to act as antigens. Those skilled in the art will further appreciate that a nucleic acid that encodes a protein that has the potential to act as an antibody ligand necessarily encodes an antigen. Those skilled in the art will further appreciate that an antigen is not limited to a full-length molecule, but can also include partial molecules. The term "antigenic" refers adjectivally to a molecule that has the properties of an antigen. The term encompasses substances that are immunogenic (i.e., immunogens) and substances that induce immunological unresponsiveness, or anergy (i.e., anergens).
[0077] An "altered antigen" is one that has a primary sequence different from that of its corresponding wild-type antigen. Altered antigens can be produced by synthetic or recombinant methods and include, but are not limited to, antigenic peptides that are differentially modified during or after translation, for example, by phosphorylation, glycosylation, cross-linking, acylation, proteolytic cleavage, linking to antibody molecules, membrane molecules, or other ligands (Ferguson et al. (1988) Ann. Rev. Biochem. 57:285-320). The synthetic or altered antigens disclosed herein are intended to bind to the same TCR as the natural epitope.
[0078] A "self-antigen," also referred to herein as a native or wild-type antigen, is an antigenic peptide that induces little or no immune response in a subject due to self-tolerance to that antigen. An example of a self-antigen is the melanoma-specific antigen gp100.
[0079] The term "passive immunity" refers to the transfer of immunity from one subject to another through the transfer of antibodies. Passive immunity can occur naturally, such as when maternal antibodies are transferred to a fetus. Passive immunity can also occur artificially, such as when an antibody composition is administered to a non-immune subject. Antibody donors and recipients can be human or non-human subjects. Antibodies can be polyclonal or monoclonal, generated in vitro or in vivo, and purified, partially purified, or unpurified, depending on the embodiment. In some embodiments disclosed herein, passive immunity is conferred to a subject in need thereof through administration of an antibody or antigen-binding fragment that specifically recognizes or binds a particular antigen. In some embodiments, passive immunity is conferred through administration of an isolated or recombinant polynucleotide that encodes an antibody or antigen-binding fragment that specifically recognizes or binds a particular antigen.
[0080] "Immune response" refers broadly to an antigen-specific response of lymphocytes to a foreign substance. The elements "immunogen" and "immunogenic" refer to a molecule that has the ability to induce an immune response. All immunogens are antigens; however, not all antigens are immunogenic. The immune response disclosed herein can be humoral (through antibody activity) or cell-mediated (through T-cell activation). The response can occur in vivo or in vitro. Those skilled in the art will appreciate that a variety of macromolecules, including proteins, nucleic acids, fatty acids, lipids, lipopolysaccharides, and polysaccharides, have the potential to be immunogenic. Those skilled in the art will further appreciate that a nucleic acid that encodes a molecule capable of eliciting an immune response necessarily encodes an immunogen. Those skilled in the art will further appreciate that an immunogen is not limited to a full-length molecule, but can include a partial molecule.
[0081] As used herein, the term "inducing an immune response in a subject" is a term well understood in the art and contemplates that an increase of at least about 2-fold, more preferably at least about 5-fold, more preferably at least about 10-fold, more preferably at least about 100-fold, even more preferably at least about 500-fold, even more preferably at least about 1000-fold, or higher, in the immune response to an antigen (or epitope) can be detected or measured after the antigen (or epitope) is introduced into the subject, relative to the immune response (if any) before the antigen (or epitope) is introduced into the subject. The immune response to an antigen (or epitope) includes, but is not limited to, the generation of antigen-specific (or epitope-specific) antibodies and the generation of immune cells expressing on their surface a molecule that specifically binds to the antigen (or epitope). Methods for determining whether an immune response to a given antigen (or epitope) has been induced are well known in the art. For example, antigen-specific antibodies can be detected using any of a variety of immunoassays known in the art, including, but not limited to, ELISA, in which binding of antibodies in a sample to immobilized antigen (or epitope) is detected with a detectably labeled secondary antibody (e.g., enzyme-labeled mouse anti-human Ig antibody).
[0082] The term "modulate an immune response" includes inducing (increasing, eliciting) an immune response; and reducing (suppressing) an immune response. An immune modulating method (or protocol) is one that modulates the immune response in a subject.
[0083] The term "vector" refers to a polynucleotide (usually DNA) that is used to artificially carry foreign genetic material into another cell, where it can be replicated or expressed. Non-limiting exemplary vectors include plasmids, viral vectors, cosmids, and artificial chromosomes. Such vectors can be derived from a variety of sources, including bacterial and viral sources. A non-limiting exemplary viral source of plasmids is the adeno-associated virus.
[0084] As used herein, the term "recombinant expression system" refers to a genetic construct for the expression of certain genetic material formed by recombination; the term "construct" is in this respect interchangeable with the term "vector" as defined herein.
[0085] "HMG domain", "high mobility group (HMG) box domain", or "HMGB" refers to an amino acid sequence involved in DNA binding (Stros et al., Cell Mol Life Sci. 64(19-20):2590-606 (2007)). In one embodiment, the structure of the HMG-box domain consists of three helices in a disordered arrangement. In another embodiment, the HMG-box domain allows the protein to bind non-B-form DNA configurations (twisted or unwound) with high affinity. HMG-box domains are found in high mobility group proteins, which are involved in regulating DNA-dependent processes such as transcription, replication and DNA repair, all of which require changes in the conformation of chromatin (Thomas (2001) Biochem. Soc. Trans. 29(Pt 4):395-401). "HMGB1" is the high mobility group box (HMGB) 1 protein, which has been reported to bind to and bend the minor groove of DNA. Recombinant or isolated proteins and polypeptides are commercially available from Atgenglobal, ProSpecBio, Protein1, and Abnova.
[0086] HMG-box proteins are found in a variety of eukaryotic organisms and can be broadly divided into two groups based on sequence-dependent and sequence-independent DNA recognition; the former usually contain one HMG-box motif, whereas the latter can contain multiple HMG-box motifs. Non-limiting examples of polypeptides that contain HMG-box domains include: HMG1 (HMGB1), HMG2 (HMGB2), HMGB3 and HMGB4 non-histone components of chromatin; SRY (sex determining region Y protein), involved in differential gonadogenesis; the SOX family of transcription factors (Harley et al. (2003) Endocr. Rev. 24(4):466-87); the sequence-specific LEF1 (lymphoid enhancer binding factor 1) and TCF-1 (T cell factor 1), involved in regulating organogenesis and thymocyte differentiation (Labbe et al. (2000) Proc. Natl. Acad. Sci. USA 97(15):8358-63); the structure-specific recognition protein SSRP, involved in transcription and replication; MTF1 mitochondrial transcription factor; nucleolar transcription factors UBF 1 / 2 (upstream binding factors), involved in transcription by RNA polymerase I; Abf2 yeast ARS-binding factor (Cho et al. (2001) Biochim. Biophys. Acta. 1522(3):175-86); the yeast transcription factors lxr1, Rox1, Nhp6b and Spp41; mating type protein (MAT) involved in sexual reproduction in fungi (Barve et al. (2003) Fungal Genet. Biol. 39(2):151-67); and the YABBY plant-specific transcription factor.
[0087] Exemplary sequences of polypeptides containing an HMG-box domain include NP_002119 (human HMGB1), NP_001124160 (human HMGB2), NP_005333 (human HMGB3) and NP_660206 (human HMGB4). About 9 to about 76 amino acid residues of human HMGB1, for example, form an HMG-box domain, and about 90 to about 138 amino acid residues form another HMG-box domain. HMGB1 fragments containing either of these two HMG-box domains also constitute, within the meaning of the present disclosure, for example, polypeptides containing an HMG-box domain. In the examples described herein, recombinant HMGB1 (derived from human and recombinantly expressed in E. coli and purified) is used as a comparator to mHMGB1(C45S) and has the following sequence: [ka]
[0088] The term "modified high mobility group-box 1 domain" as used herein refers to, for example, a polypeptide having the consensus sequence of HMGB1 from humans: [ka] This refers to HMGB1 that has been mutated via substitution of cysteine residues at positions 23, 45, and / or 106 based on the following:
[0089] Non-limiting exemplary sequences of modified high mobility group-box 1 domains include, but are not limited to, the following:
[0090] mHMGB1(C23S): [ka]
[0091] mHMGB1(C45S): [ka]
[0092] mHMGB1(C106S): [ka]
[0093] mHMGB1 (C23S, C45S - double mutant): [ka]
[0094] mHMGB1 (C23S, C106S - double mutant): [ka]
[0095] mHMGB1 (C45S, C106S - double mutant): [ka]
[0096] mHMGB1 (C23S, C45S, C106S - triple mutant): [ka]
[0097] Nucleic acid sequences encoding these modified high mobility group-box 1 domains are also provided herein below:
[0098] mHMGB1(C23S): [ka]
[0099] mHMGB1(C45S): [ka]
[0100] mHMGB1(C106S): [ka] [ka]
[0101] mHMGB1 (C23S, C45S - double mutant): [ka]
[0102] mHMGB1 (C23S, C106S - double mutant): [ka]
[0103] mHMGB1 (C45S, C106S - double mutant): [ka]
[0104] mHMGB1 (C23S, C45S, C106S - triple mutant): [ka]
[0105] It will be appreciated that the term "modified high mobility group-box 1 domain" further encompasses those equivalents having at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 98% or at least about 99% identity to the HMGB1 consensus sequence and containing the same substitutions at corresponding positions in the equivalent sequence based on alignment to the HMGB1 consensus sequence.
[0106] It is recognized that among the equivalents of the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S in modified high mobility group box 1.
[0107] The corresponding amino acid substitutions resulting in the modified high mobility group-box 2 are the polypeptides of the consensus sequence of HMGB2 from humans: [ka] Based on this, the cysteine residues at positions 23, 45, and / or 106 may be used.
[0108] Non-limiting exemplary sequences of modified high mobility group-box 2 domains include, but are not limited to, the following:
[0109] mHMGB2(C23S): [ka]
[0110] mHMGB2(C45S): [ka]
[0111] mHMGB2(C106S): [ka]
[0112] mHMGB2 (C23S, C45S - double mutant): [ka] [ka]
[0113] mHMGB2 (C23S, C106S - double mutant): [ka]
[0114] mHMGB2 (C45S, C106S - double mutant): [ka]
[0115] mHMGB2 (C23S, C45S, C106S - triple mutant): [ka]
[0116] Nucleic acid sequences encoding these modified high mobility group-box 2 domains are also provided herein below:
[0117] mHMGB2(C23S): [ka]
[0118] mHMGB2(C45S): [ka]
[0119] mHMGB2(C106S): [ka]
[0120] mHMGB2 (C23S, C45S - double mutant): [ka] [ka]
[0121] mHMGB2 (C23S, C106S - double mutant): [ka]
[0122] mHMGB2 (C45S, C106S - double mutant): [ka]
[0123] mHMGB2 (C23S, C45S, C106S - triple mutant): [ka]
[0124] The corresponding amino acid sequence substitutions resulting in the modified high mobility group-box 3 are the polypeptides of the consensus sequence of HMGB3 from humans: [ka] Based on this, the cysteine residues at positions 23, 45, and / or 104 may be used.
[0125] Non-limiting exemplary sequences of modified high mobility group-box 2 domains include, but are not limited to, the following:
[0126] mHMGB3(C23S): [ka]
[0127] mHMGB3(C45S): [ka]
[0128] mHMGB3(C104S): [ka]
[0129] mHMGB3 (C23S, C45S - double mutant): [ka]
[0130] mHMGB3 (C23S, C104S - double mutant): [ka]
[0131] mHMGB3 (C45S, C104S - double mutant): [ka]
[0132] mHMGB3 (C23S, C45S, C104S - triple mutant): [ka]
[0133] Nucleic acid sequences encoding these modified high mobility group-box 2 domains are also provided herein below:
[0134] mHMGB3(C23S): [ka] [ka]
[0135] mHMGB3(C45S): [ka]
[0136] mHMGB3(C104S): [ka] [ka]
[0137] mHMGB3 (C23S, C45S - double mutant): [ka]
[0138] mHMGB3 (C23S, C104S - double mutant): [ka]
[0139] mHMGB3 (C45S, C104S - double mutant): [ka] [ka]
[0140] mHMGB3 (C23S, C45S, C104S - triple mutant): [ka]
[0141] The corresponding amino acid sequence substitutions resulting in the modified high mobility group-box 2 are the polypeptides of the consensus sequence of HMGB2 from humans: [ka] Based on this, the cysteine residues at positions 45, 104, 164, and / or 178 may be used.
[0142] Non-limiting exemplary sequences of modified high mobility group-box 2 domains include, but are not limited to, the following:
[0143] mHMGB4(C45S): [ka] [ka]
[0144] mHMGB4(C104S): [ka]
[0145] mHMGB4(C164S): [ka]
[0146] mHMGB4(C178S): [ka]
[0147] mHMGB4 (C45S, C104S - double mutant): [ka]
[0148] mHMGB4 (C45S, C164S - double mutant): [ka]
[0149] mHMGB4 (C45S, C178S - double mutant): [ka] [ka]
[0150] mHMGB4 (C104S, C164S - double mutant): [ka]
[0151] mHMGB4 (C104S, C178S - double mutant): [ka]
[0152] mHMGB4 (C164S, C178S - double mutant): [ka]
[0153] mHMGB4 (C45S, C104S, C164S - triple mutant): [ka]
[0154] mHMGB4 (C45S, C104S, C178S - triple mutant): [ka]
[0155] mHMGB4 (C45S, C164S, C178S - triple mutant): [ka]
[0156] mHMGB4(C104S, C164S, C178S) - Triple Mutant): [ka]
[0157] mHMGB4 (C45S, C104S, C164S, C178S - quadruple mutant): [ka]
[0158] Nucleic acid sequences encoding these modified high mobility group-box 2 domains are also provided herein below:
[0159] mHMGB4(C45S): [ka]
[0160] mHMGB4(C104S): [ka] [ka]
[0161] mHMGB4(C164S): [ka]
[0162] mHMGB4(C178S): [ka]
[0163] mHMGB4 (C45S, C104S - double mutant): [ka] [ka]
[0164] mHMGB4 (C45S, C164S - double mutant): [ka]
[0165] mHMGB4 (C45S, C178S - double mutant): [ka]
[0166] mHMGB4 (C104S, C164S - double mutant): [ka] [ka]
[0167] mHMGB4 (C104S, C178S - double mutant): [ka]
[0168] mHMGB4 (C164S, C178S - double mutant): [ka] [ka]
[0169] mHMGB4 (C45S, C104S, C164S - triple mutant): [ka]
[0170] mHMGB4 (C45S, C104S, C178S - triple mutant): [ka]
[0171] mHMGB4 (C45S, C164S, C178S - triple mutant): [ka] [ka]
[0172] mHMGB4(C104S, C164S, C178S) - Triple Mutant): [ka]
[0173] mHMGB4 (C45S, C104S, C164S, C178S - quadruple mutant): [ka]
[0174] Modes for carrying out the disclosure Applicants show herein that while DNABII proteins stabilize the eDNA-dependent extracellular matrix of biofilms, recombinant HMGB1 (rHMGB1) disrupted preformed bacterial biofilms in vitro (Table 1), cleared NTHI biofilms from the chinchilla middle ear in an experimental model of otitis media (OM) (Figures 1A-1B), and inhibited Burkholderia cenocepacia biofilm development in the mouse respiratory tract, directly resulting in reduced bacterial load (Figures 2A-2D).
[0175] Although rHMGB1 has been shown to be effective in disrupting biofilms in vitro and in vivo, it is also well documented that it induces a strong inflammatory response that can be potentially harmful to the host. Several post-translational modifications (PTMs), including acetylation, phosphorylation, methylation, glycosylation, ADP-ribosylation, and oxidation of cysteine residues, have been described for HMGB1 that regulate its location (nuclear, cytoplasmic, or extracellular), function, and ability to bind DNA (reviewed in (Kang et al. 2014)). Human HMGB1 contains three cysteine residues at positions 23, 45, and 106, the oxidation of which affects its inflammatory properties (Kazama et al. 2008). HMGB1, which contains a C106 thiol group and a C23-C45 disulfide bond, triggers inflammation, while terminally oxidized cysteines promote the resolution of inflammation (Yang et al. 2012).
[0176] In the disclosed study, applicants generated a variant form of HMGB1 (mHMGB1), in which applicants replaced the cysteine at position 45 with serine (C45S). Applicants showed that mHMGB1 (C45S) is effective in disrupting preformed biofilms in vitro formed by multiple human pathogens, clearing NTHI biofilms in experimental models of OM, and reducing B.cenocepacia bacterial load in mouse airways, while it does not enhance inflammatory responses. Applicants' data suggest that applicants have generated an HMGB1 variant (mHMGB1) that retains the desired anti-biofilm function against multiple human pathogens, but is defective in raising undesirable strong pro-inflammatory responses. Furthermore, this study suggests that other equivalent modifications of HMGB1 (e.g., C23S and C106S) may produce similar results. Thus, Applicants generate a triple mutant HMGB1 comprising the modifications C23S, C45S, and C106S, as well as further mutant HMGB1 comprising one or more modifications selected from the group of C23S, C45S, and C106S.
[0177] Applicant's approach is an improvement over current technology in that it does not rely on compounds with bactericidal activity that put additional pressure on the bacteria to develop resistance mechanisms, but rather targets the biofilm extracellular matrix, resulting in the disruption of the biofilm leading to resolution of disease in the absence of excessive inflammation.
[0178] The methods and compositions are useful in treating a large number of different biofilm-mediated infections, including, but not limited to, otitis media, urinary tract infections, pneumonia, gingivitis, peri-implantitis, periodontitis, cystic fibrosis, endocarditis and burn wound infections.
[0179] The methods and compositions are useful in combination with antibiotics or other antimicrobials to "sterilize" the target site of device insertion to prevent device-associated infections.
[0180] C45S recombinant HMGB1 or modified HMGB1(C45S) ("mHMGB1(C45S)") has been shown to disrupt existing biofilms both in vitro and in vivo (in two mammalian models). Dispersing large amounts of bacteria from biofilms to planktonic conditions in vivo may have potential drawbacks in that these planktonic bacteria may now gain access to other sites that they did not have access to before resulting in potential second site infection. This dispersal effect may also result in sepsis. In addition to the fact that none of these outcomes have been observed with mHMGB1 and that depending on the site of biofilm infection these potential pitfalls may be moot, there are means to circumvent these potential limitations. Indeed, the C45S mutation appears to increase the affinity of the molecule for branched DNA structures (extracellular DNA in bacterial biofilms is thought to constitute these structures) and also dampen its inflammatory response, thus conferring a better therapeutic response.
[0181] Thus, the aspects disclosed herein relate to a modified high mobility group-box 1 domain comprising one or more or all of the substitutions selected from the group of C23S, C45S, and C106S, an isolated or recombinant polynucleotide encoding the modified high mobility group-box 1 domain, a vector comprising the isolated or recombinant polynucleotide, and a composition comprising an effective amount of the modified high mobility group-box 1 domain and / or the isolated or recombinant polynucleotide and / or the vector. In one aspect, the polynucleotide is DNA, and in another aspect, the polynucleotide is RNA. Also provided is a recombinant method of producing the mHMGB1 polypeptide by expressing the polynucleotide in a prokaryotic or eukaryotic system. In a further aspect, the protein produced in the system is isolated. Thus, the disclosure also provides a polypeptide produced in a prokaryotic and eukaryotic host cell system. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain contains the substitutions C23S, C45S, and C106S.
[0182] A further aspect relates to a method for inhibiting, competing or titrating the binding of deoxyribonucleic acid B II (DNABII) polypeptide to microbial DNA in a biofilm, comprising contacting the microbial DNA in the biofilm with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S and C106S, or any one or more of the compositions disclosed above, thereby inhibiting, competing or titrating the binding of the DNABII polypeptide to the microbial DNA. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S and C106S. In some embodiments, the contacting is in vitro or in vivo. In some embodiments, the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), and / or Aggregatibacter actinomycetemcomitans. In some embodiments, the method further comprises administering, and optionally coating, an effective amount of an antibiotic to the surface.
[0183] Yet another aspect relates to a method for preventing the formation of a biofilm on a surface, comprising contacting the surface with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising one or more or all substitutions selected from the group of C23S, C45S, and C106S, or any one or more of the compositions disclosed above, optionally coated, thereby inhibiting, competing, or titrating the binding of a DNABII polypeptide to microbial DNA during biofilm formation. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S. In some embodiments, the contacting is in vitro or in vivo. In some embodiments, the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), and / or Aggregatibacter actinomycetemcomitans. In some embodiments, the method further comprises administering, and optionally coating, an effective amount of an antibiotic to the surface.
[0184] A further aspect relates to a method for preventing or treating microbial infection in a subject that produces a biofilm, comprising administering an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S, or any one or more of the compositions disclosed above, thereby inhibiting, competing, or titrating the binding of DNABII polypeptide to microbial DNA. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C23S, C45S, and C106S. In some embodiments, the biofilm is formed by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), and / or Aggregatibacter actinomycetemcomitans. In some embodiments, the method further comprises administering an effective amount of an antibiotic.
[0185] It is recognized that among the equivalents to the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S of modified high mobility group box 1. For modified high mobility group-box 2, the corresponding cysteine residues are found at positions 23, 45, and 106; for modified high mobility group-box 3, the corresponding cysteine residues are found at positions 23, 45, and 104; and for modified high mobility group-box 4, the corresponding cysteine residues are found at positions 45, 104, 164, and 178. Accordingly, Applicants believe that the above-mentioned aspects disclosed with respect to modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S are equally applicable to the above-mentioned high mobility group-box species having one or more cysteine to serine substitutions at the referred positions (e.g. modified high mobility group-box 2 containing one or more substitutions selected from the group of C23S, C45S, and C106S; modified high mobility group-box 3 containing one or more substitutions selected from the group of C23S, C45S, and C104S; and modified high mobility group-box 4 containing one or more substitutions selected from the group of C45S, C104S, C164S, and C178S).
[0186] Modes for carrying out the disclosure Polypeptides Aspects disclosed herein relate to modified high mobility group-box 1 domains comprising one or more substitutions selected from the group of C23S, C45S, and C106S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises one, two, or all three substitutions C23S, C45S, and C106S.
[0187] It is recognized that among the equivalents to the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S of modified high mobility group box 1. For modified high mobility group-box 2, the corresponding cysteine residues are found at positions 23, 45, and 106; for modified high mobility group-box 3, the corresponding cysteine residues are found at positions 23, 45, and 104; and for modified high mobility group-box 4, the corresponding cysteine residues are found at positions 45, 104, 164, and 178. Accordingly, Applicants believe that the aforementioned polypeptide aspects disclosed with respect to modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S are equally applicable to the aforementioned high mobility group-box species having one or more cysteine to serine substitutions at the referenced positions (e.g. modified high mobility group-box 2 containing one or more substitutions selected from the group of C23S, C45S, and C106S; modified high mobility group-box 3 containing one or more substitutions selected from the group of C23S, C45S, and C104S; and modified high mobility group-box 4 containing one or more substitutions selected from the group of C45S, C104S, C164S, and C178S).
[0188] The proteins and polypeptides can be obtained by many processes known to those skilled in the art, including purification methods, chemical synthesis methods and recombinant methods. Polypeptides can be isolated from preparations such as host cell systems by methods such as immunoprecipitation with antibodies, and standard techniques such as gel filtration, ion exchange, reverse phase and affinity chromatography. For such methodologies, see, for example, Deutscher et al. (1999) Guide To Protein Purification: Methods In Enzymology (Vol. 182, Academic Press). Thus, the present invention also provides processes for obtaining these polypeptides, as well as products obtainable and obtained by these processes.
[0189] The polypeptides can also be obtained by chemical synthesis using commercially available automated peptide synthesizers (e.g., those manufactured by Perkin / Elmer / Applied Biosystems, Inc., Foster City, Calif., USA, Model 430A or 431A). The synthesized polypeptides can be precipitated and further purified, for example, by high performance liquid chromatography (HPLC). Thus, the present invention also provides a process for chemically synthesizing the proteins of the present invention by providing the protein sequence and the reagents (amino acids and enzymes) and linking the amino acids together in the proper orientation and linear sequence.
[0190] Alternatively, the proteins and polypeptides can be obtained by well-known recombinant methods or mutagenesis using the host cells and vector systems described herein, for example as described in Sambrook et al. (2012) supra.
[0191] The polypeptides of the present invention can also be combined with various solid phase carriers (e.g., implants, stents, pastes, gels, dental or medical implants) or liquid phase carriers (e.g., beads, sterile or aqueous solutions, pharma- ceutically acceptable carriers, suspensions or emulsions). Examples of non-aqueous solvents include propyl ethylene glycol, polyethylene glycol and vegetable oils. When used to prepare antibodies or induce immune responses in vivo, the carriers can also contain adjuvants useful for non-specifically increasing specific immune responses. Those skilled in the art can easily determine whether an adjuvant is required and select one. However, for illustrative purposes only, suitable adjuvants include, but are not limited to, Freund's complete and incomplete adjuvants, inorganic salts and polynucleotides. Other suitable adjuvants include adjuvants derived from monophosphoryl lipid A (MPL), mutant derivatives of E. coli heat-labile enterotoxin, mutant derivatives of cholera toxin, CPG oligonucleotides and squalene.
[0192] Polynucleotides and Vectors Aspects disclosed herein relate to an isolated or recombinant polynucleotide encoding a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S, and / or a vector comprising the isolated or recombinant polynucleotide. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S.
[0193] In general, methods for packaging genetic material (e.g., DNA or RNA) into one or more vectors are well known in the art. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S. For example, the genetic material can be packaged using a packaging vector and cell line and introduced via traditional recombination methods.
[0194] It is recognized that among the equivalents to the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S of modified high mobility group box 1. For modified high mobility group-box 2, the corresponding cysteine residues are found at positions 23, 45, and 106; for modified high mobility group-box 3, the corresponding cysteine residues are found at positions 23, 45, and 104; and for modified high mobility group-box 4, the corresponding cysteine residues are found at positions 45, 104, 164, and 178. Accordingly, Applicants believe that the isolated polynucleotides and vectors disclosed with respect to a modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S are equally applicable to the aforementioned high mobility group-box species having one or more cysteine to serine substitutions at the referenced positions (e.g., a modified high mobility group-box 2 containing one or more substitutions selected from the group of C23S, C45S, and C106S; a modified high mobility group-box 3 containing one or more substitutions selected from the group of C23S, C45S, and C104S; and a modified high mobility group-box 4 containing one or more substitutions selected from the group of C45S, C104S, C164S, and C178S).
[0195] In some embodiments, the packaging vector may include, but is not limited to, retroviral vector, lentiviral vector, adenoviral vector, and adeno-associated viral vector (optionally AAV8). The packaging vector includes elements and sequences that facilitate the delivery of genetic material to cells. For example, the retroviral construct is a packaging plasmid that includes at least one retroviral helper DNA sequence derived from a replication-incompetent retroviral genome to generate virion proteins that encode all virion proteins required for packaging replication-incompetent retroviral vectors in trans and can package replication-incompetent retroviral vectors at high titers without generating replication-competent helper viruses. The retroviral DNA sequence lacks the region that encodes the native enhancer and / or promoter of the viral 5' LTR of the virus, lacks both the psi functional sequence and 3' LTR that are responsible for packaging the helper genome, but encodes an exogenous polyadenylation site (e.g., SV40 polyadenylation site), and an exogenous enhancer and / or promoter that directs efficient transcription in the cell type in which virus production is desired. The retrovirus is a leukemia virus (e.g., Moloney Murine Leukemia Virus (MMLV)), Human Immunodeficiency Virus (HIV), or Gibbon Ape Leukemia Virus (GALV). The foreign enhancer and promoter can be the human cytomegalovirus (HCMV) immediate-immediate (IE) enhancer and promoter, the Moloney Murine Sarcoma Virus (MMSV) enhancer and promoter (U3 region), the Rous Sarcoma Virus (RSV) U3 region, the Spleen Focus Forming Virus (SFFV) U3 region, or the HCMV IE enhancer linked to the native Moloney Murine Leukemia Virus (MMLV) promoter.
[0196] The retroviral packaging plasmid may consist of two retroviral helper DNA sequences encoded by a plasmid-based expression vector, for example, where the first helper sequence contains a cDNA encoding the gag and pol proteins of ecotropic MMLV or GALV, and the second helper sequence contains a cDNA encoding the env protein. The Env gene that determines the host range may be derived from xenotropic, amphotropic, ecotropic, polytropic (mink focus forming) or 10A1 murine leukemia virus env protein, or a gene encoding a gibbon ape leukemia virus (GALV) env protein, a human immunodeficiency virus env (gp160) protein, a vesicular stomatitis virus (VSV) G protein, a human T-cell leukemia (HTLV) type I and II env gene product, a chimeric envelope gene derived from a combination of one or more of the aforementioned env genes, or a chimeric envelope gene encoding the cytoplasmic and transmembrane portions of the aforementioned env gene products and a monoclonal antibody directed against a specific surface molecule on a desired target cell. Similar vector-based systems may use other vectors, such as the Sleeping Beauty vector or transposon elements.
[0197] The resulting packaged expression system can then be introduced via a suitable route of administration, as discussed in detail with respect to the method aspects disclosed herein.
[0198] composition A further aspect relates to a composition comprising an effective amount of a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S, and / or the isolated or recombinant polynucleotide as described above, and / or the vector as described above. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S.
[0199] It is recognized that among the equivalents to the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S of modified high mobility group box 1. For modified high mobility group-box 2, the corresponding cysteine residues are found at positions 23, 45, and 106; for modified high mobility group-box 3, the corresponding cysteine residues are found at positions 23, 45, and 104; and for modified high mobility group-box 4, the corresponding cysteine residues are found at positions 45, 104, 164, and 178. Accordingly, Applicants believe that the composition aspects disclosed with respect to modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S are equally applicable to the aforementioned high mobility group-box species having one or more cysteine to serine substitutions at the referenced positions (e.g., modified high mobility group-box 2 containing one or more substitutions selected from the group of C23S, C45S, and C106S; modified high mobility group-box 3 containing one or more substitutions selected from the group of C23S, C45S, and C104S; and modified high mobility group-box 4 containing one or more substitutions selected from the group of C45S, C104S, C164S, and C178S).
[0200] Briefly, the pharmaceutical compositions of the present disclosure, including but not limited to any one of the claimed compositions, may comprise a modified high mobility group-box 1 domain as described herein in combination with one or more pharma- ceutically or physiologically acceptable carriers, diluents or excipients.
[0201] Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for the purposes of the disclosure. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such using routine experimentation.
[0202] Such compositions may also include buffers (e.g., neutral buffered saline, phosphate buffered saline, etc.); carbohydrates (e.g., glucose, mannose, sucrose or dextran, mannitol); proteins; polypeptides or amino acids (e.g., glycine); antioxidants; chelating agents (e.g., EDTA or glutathione); adjuvants (e.g., aluminum hydroxide); and preservatives. The compositions of the present disclosure may be formulated for oral, intravenous, topical, enteral, and / or parenteral administration. In certain embodiments, the compositions of the present disclosure are formulated for intravenous administration.
[0203] The administration of the composition can be effected in one dose, continuously or intermittently throughout the course of treatment. The method for determining the most effective means and dosage of administration is known to those skilled in the art and varies with the composition used in treatment, the therapeutic purpose and the subject being treated. Single or multiple administrations can be performed with the dosage level and pattern selected by the treating physician. Appropriate dosage formulations and methods of administering the agent are known in the art. In a further aspect, the cells and compositions of the present disclosure can be administered in combination with other treatments.
[0204] The vectors, recombinant expression systems, and / or compositions are administered to a host using methods known in the art. This administration of the compositions of the present disclosure can be done to generate animal models of the desired disease, disorder, or condition for experimental and screening assays.
[0205] Briefly, the pharmaceutical compositions of the present disclosure, including but not limited to any one of the claimed compositions, may comprise one or more vectors or recombinant expression systems as described herein in combination with one or more pharma- ceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers (e.g., neutral buffered saline, phosphate buffered saline, etc.); carbohydrates (e.g., glucose, mannose, sucrose or dextran, mannitol); proteins; polypeptides or amino acids (e.g., glycine); antioxidants; chelating agents (e.g., EDTA or glutathione); adjuvants (e.g., aluminum hydroxide); and preservatives. The compositions of the present disclosure may be formulated for oral, intravenous, topical, enteral, and / or parenteral administration. In certain embodiments, the compositions of the present disclosure are formulated for intravenous administration.
[0206] The pharmaceutical compositions of the present disclosure can be administered in a manner appropriate to the disease, disorder, or condition to be treated or prevented. The amount and frequency of administration will be determined by factors such as the condition of the patient, the type and severity of the patient's disease, and the appropriate dosage can be determined by clinical trials.
[0207] treatment Aspects disclosed herein relate to therapeutic methods. For example, aspects relate to a method for inhibiting, competing or titrating the binding of deoxyribonucleic acid B II (DNABII) polypeptide to microbial DNA in biofilm, comprising contacting the microbial DNA in the biofilm with an effective amount of an isolated or recombinant polypeptide comprising modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S and C106S, or any one or more of the compositions disclosed above, thereby inhibiting, competing or titrating the binding of DNABII polypeptide to the microbial DNA. In some embodiments, the modified high mobility group-box 1 domain comprises substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises substitutions C23S, C45S and C106S. In some embodiments, the contacting is in vitro or in vivo.
[0208] A further aspect relates to a method for preventing the formation of biofilm on a surface, comprising contacting the surface with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S, or any one or more of the compositions disclosed above, optionally coated, thereby inhibiting, competing, or titrating the binding of DNABII polypeptide to microbial DNA during biofilm formation. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S. In some embodiments, the contacting is in vitro or in vivo.
[0209] Further aspects relate to a method for preventing or treating microbial infection in a subject that produces biofilm, comprising administering an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S, or any one or more of the compositions disclosed above, thereby inhibiting, competing, or titrating the binding of DNABII polypeptide to microbial DNA. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C23S, C45S, and C106S.
[0210] In some aspects, a polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S comprises, or alternatively consists essentially of, or even consists of a biological equivalent to any of the polypeptides described above.
[0211] It is recognized that among the equivalents to the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S of modified high mobility group box 1. For modified high mobility group-box 2, the corresponding cysteine residues are found at positions 23, 45, and 106; for modified high mobility group-box 3, the corresponding cysteine residues are found at positions 23, 45, and 104; and for modified high mobility group-box 4, the corresponding cysteine residues are found at positions 45, 104, 164, and 178. Accordingly, Applicants believe that the method aspects disclosed with respect to modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S are equally applicable to the aforementioned high mobility group-box species having one or more cysteine to serine substitutions at the referenced positions (e.g., modified high mobility group-box 2 containing one or more substitutions selected from the group of C23S, C45S, and C106S; modified high mobility group-box 3 containing one or more substitutions selected from the group of C23S, C45S, and C104S; and modified high mobility group-box 4 containing one or more substitutions selected from the group of C45S, C104S, C164S, and C178S).
[0212] In some aspects, the isolated or recombinant protein is a mammalian protein. In certain aspects, the mammalian protein is a human protein.
[0213] Any of the above methods may further comprise, alternatively consist essentially of, or even further consist of administering to a subject, which in one aspect is a non-human animal or a human patient, an effective amount of one or more of an antimicrobial agent, an antigenic peptide, or an adjuvant.
[0214] The polypeptide is administered by methods including topically, transdermally, sublingually, rectally, vaginally, ophthalmically, subcutaneously, intramuscularly, intraperitoneally, urethrally, intranasally, by inhalation, or orally.
[0215] In some aspects, the subject is a pediatric patient and the polypeptide is administered in a formulation for the pediatric patient.
[0216] In any of the above embodiments, the biofilm may contain microbial DNA derived from a microorganism identified in Table 1.
[0217] In one embodiment, the polypeptide is administered locally to the microbial infection.
[0218] In one embodiment, the present disclosure provides a method for inducing or providing an immune response in a subject in need thereof, comprising, or alternatively consisting essentially of, or even consisting of administering to the subject an effective amount of a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S. In another embodiment, the administration is local to the location where an immune response is desired. Examples of modified high mobility group-box 1 domains comprising one or more substitutions selected from the group of C23S, C45S, and C106S are described above. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S.
[0219] The isolated or recombinant protein may be a mammalian protein, or in certain aspects, a human protein. The subject, in some aspects, is a non-human animal or a human patient.
[0220] The agent and composition of the present invention can be administered simultaneously or sequentially with other antimicrobial agents and / or surface antigens.In one particular aspect, administration is administered locally at the site of infection.Other non-limiting examples of administration include one or more methods including transdermally, sublingually, rectally, vaginally, ocularly, subcutaneously, intramuscularly, intraperitoneally, urethrally, intranasally, by inhalation, or orally.
[0221] In one embodiment, there is also provided the use of any of the above polypeptides comprising, alternatively consisting essentially of, or even further consisting of a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S for the manufacture of a medicament in disrupting biofilms or inhibiting, preventing, or treating biofilm-producing microbial infections. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S.
[0222] For some of these methods, the contacting step can be performed in vitro or in vivo. When the contacting step is in vitro, the method provides a means to determine the effectiveness of the agent of the present invention before animal or clinical studies, and can be used to determine whether the agent of the present invention functions synergistically with additional antimicrobial substances. When performed in vivo in an animal model, the method provides a means to determine the effectiveness of the agent of the present invention before studies in human patients, and can be used to determine whether the agent of the present invention functions synergistically with additional antimicrobial substances (e.g., antibiotics).
[0223] Microbial infections and diseases that can be treated by the methods of the invention include infections with organisms identified in Table 1, such as Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-encapsulated Haemophilus influenzae (NTHI), or Aggregatibacter actinomycetemcomitans. These microbial infections can be present in the upper, middle or lower respiratory tract (otitis, sinusitis or bronchitis), but also in exacerbations of chronic obstructive pulmonary disease (COPD), chronic cough, cystic fibrosis (CF) and community-acquired pneumonia (CAP) complications and / or primary causes.
[0224] Infections can also occur in the oral cavity (dental caries, periodontitis) and can be caused by Streptococcus mutans, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans. Infections can also be localized in the skin (abscesses, "staphylococcal" infections, impetigo, secondary infections of burns, Lyme disease) and can be caused by Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa and Borrelia burdorferi. Urinary tract infections (UTIs) can also be treated and are typically caused by Escherichia coli. Infections of the gastrointestinal (GI) tract (diarrhea, cholera, gallstones, stomach ulcers) are typically caused by Salmonella enterica serovar, Vibrio cholerae and Helicobacter pylori. Infections of the reproductive tract include those typically caused by Neisseria gonorrhoeae. Infections of the bladder or of indwelling devices may be caused by Enterococcus faecalis. Infections typically caused by various bacteria associated with implanted prosthetic devices (e.g., hip or knee replacements) or dental implants or medical devices (e.g., pumps or monitoring systems) may be treated by the methods of the present invention. These devices may be coated with or conjugated to agents as described herein.
[0225] Infection caused by Streptococcus agalactiae is the main cause of bacterial sepsis in newborns. Such infections can also be treated by the methods of the present invention. Similarly, infections caused by Neisseria meningitidis, which can cause meningitis, can also be treated.
[0226] Thus, the administration routes applicable to the method of the present invention include intranasal, intramuscular, intratracheal, subcutaneous, intradermal, topical application, intravenous, rectal, nasal, oral, and other enteral and parenteral administration routes. The administration routes can be combined (if desired) or adjusted depending on the drug and / or the desired effect. The active agent can be administered in a single dose or in multiple doses. The embodiments of the methods and suitable routes for delivery include systemic or local routes. In general, the administration routes suitable for the method of the present invention include, but are not limited to, enteral, parenteral, or inhalation routes.
[0227] Parenteral administration routes other than inhalation administration include, but are not limited to, topical, transdermal, subcutaneous, intramuscular, intraorbital, intracapsular, intrathecal, intrasternal and intravenous routes, i.e., any route of administration other than via the digestive tract. Parenteral administration can be carried out to effect systemic or local delivery of the inhibitory agent. When systemic delivery is desired, administration typically requires invasive or systemically absorbed topical or mucosal administration of pharmaceutical preparations.
[0228] The compounds of the present invention can also be delivered to a subject by enteral administration, including, but not limited to, oral and rectal (e.g., using a suppository) delivery.
[0229] Methods for administering the active agent through the skin or mucous membrane include, but are not limited to, topical application of suitable pharmaceutical preparations, transcutaneous transmission, transdermal transmission, injection and epidermal administration.For transdermal transmission, absorption enhancers or iontophoresis are suitable methods.Iontophoretic transmission can be achieved using commercially available "patches" that continuously deliver their products via electrical pulses through unbroken skin for several days or longer.
[0230] In various embodiments of the methods of the invention, the active is orally administered continuously, daily, at least once per day (QD), and in various embodiments, twice (BID), three times (TID) or even four times per day. Typically, the therapeutically effective daily dose is at least about 1 mg, or at least about 10 mg, or at least about 100 mg, or about 200 to about 500 mg, and sometimes as much as about 1 g to about 2.5 g, depending on the compound.
[0231] Administration may be accomplished according to the methods of the present invention using capsules, tablets, oral suspensions, suspensions for intramuscular injection, suspensions for intravenous infusion, gels or creams for topical application, or suspensions for intra-articular injection.
[0232] Dosage, toxicity and therapeutic efficacy of the compositions described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the dose lethal to 50% of the population) and ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD50 / ED50. Compositions that exhibit high therapeutic indices are preferred. Compounds that exhibit toxic side effects may be used, but care should be taken to design a delivery system that targets such compounds to the site of affected tissues in order to minimize potential damage to non-infected cells, thereby reducing side effects.
[0233] Data obtained from cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds is preferably within a range of circulating concentrations that includes the ED50 with little or no toxicity. The dosage can vary within this range depending on the dosage form used and the route of administration utilized. For any compound used in the method, the therapeutically effective dose can be initially predicted from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound that achieves half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.
[0234] In some embodiments, the effective amount of the composition sufficient to achieve a therapeutic or prophylactic effect ranges from about 0.000001 mg / kilogram body weight / dose to about 10,000 mg / kilogram body weight / dose. Suitably, the dosage range is from about 0.0001 mg / kilogram body weight / dose to about 100 mg / kilogram body weight / dose. The dose may be provided as an initial dose, followed by one or more "booster" doses. The booster dose may be provided 1 day, 2 days, 3 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, or 12 months after the initial dose. In some embodiments, the booster dose is administered after evaluation of the subject's response to the previous dose.
[0235] Those skilled in the art will recognize that certain factors may influence the dosage and timing required to effectively treat a subject, including, but not limited to, the severity of the disease or disorder, previous treatments, the general health and / or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the therapeutic compositions described herein may include a single treatment or a series of treatments.
[0236] Combination therapy The compositions and related methods of the invention may be used in combination with the administration of other therapeutic agents, including, but not limited to, DNase enzymes, antibiotics, antimicrobial agents, or other antibodies.
[0237] In some embodiments, the methods and compositions include a deoxyribonuclease (DNase) enzyme, such as DNase, which acts synergistically with the compositions of the present disclosure. DNase is any enzyme that catalyzes the cleavage of phosphodiester bonds in the DNA backbone. Three non-limiting examples of DNase enzymes known to target not only cruciform structures but also various secondary structures of DNA include DNAse I, T4 EndoVII, and T7 Endo I. In certain embodiments, the effective amount of anti-DNABII antibody required to destabilize biofilms is reduced when combined with DNase. When administered in vitro, the DNase can be added directly to the assay or in a suitable buffer known to stabilize the enzyme. The effective unit dose of DNase and assay conditions can vary and can be optimized according to procedures known in the art.
[0238] In other embodiments, the methods and compositions may be combined with antibiotics and / or antimicrobial agents. Antimicrobial agents are agents that kill or inhibit the growth of microorganisms (e.g., bacteria, fungi, or protozoa). Biofilms are generally resistant to the action of antibiotics, but the compositions and methods described herein may be used to sensitize biofilm-associated infections to traditional therapies for treating the infection. In other embodiments, the use of antibiotics or antimicrobial agents in combination with the methods and compositions described herein allows for a reduction in the effective amount of antimicrobial agents and / or biofilm-reducing agents. Some non-limiting examples of antimicrobial agents and antibiotics useful in combination with the methods of the present invention include minocycline, amoxicillin, amoxicillin-clavulanate, cefdinir, azithromycin, and sulfamethoxazole-trimethoprim. The therapeutically effective dose of antimicrobial agents and / or antibiotics in combination with the biofilm-reducing agents may be readily determined by traditional methods. In some embodiments, the dose of the antimicrobial agent in combination with the biofilm reduction agent is the average effective dose shown to be effective in other bacterial infections (e.g., bacterial infections where the etiology of infection does not involve biofilms.) In other embodiments, the dose is 0.1, 0.15, 0.2, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.8, 0.85, 0.9, 0.95, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, or 5 times the average effective dose. The antibiotic or antimicrobial agent may be added prior to, simultaneously with, or after the addition of the anti-DNABII antibody.
[0239] In other embodiments, the methods and compositions can be combined with antibodies to treat the bacterial infection. One example of an antibody useful in combination with the methods and compositions described herein is an antibody directed against an unrelated outer membrane protein (e.g., OMP P5). Treatment with this antibody alone does not debulk biofilms in vitro. Combination therapy with this antibody and a biofilm-reducing agent produces a greater effect than can be achieved by either agent used alone at the same concentration. Other antibodies that can produce synergistic effects when combined with biofilm-reducing agents or methods to reduce biofilms include anti-rsPilA, anti-OMP26, anti-OMP P2, and anti-intact OMP preparations.
[0240] The compositions and methods described herein can be used to sensitize biofilm-associated bacterial infections to common therapeutic modalities that are effective in treating non-biofilm-associated bacterial infections, but are otherwise ineffective in treating biofilm-associated bacterial infections.In other embodiments, the compositions and methods described herein can be used in combination with therapeutic modalities that are effective in treating biofilm-associated bacterial infections, but such combination of additional therapeutic and biofilm-reducing agents or methods creates a synergistic effect, such that the effective dose of either the biofilm-reducing agent or the additional therapeutic agent can be reduced.In other cases, such combination of additional therapeutic and biofilm-reducing agents or methods creates a synergistic effect, such that treatment is enhanced.Enhanced treatment can be evidenced by a shorter amount of time required to treat the infection.
[0241] The additional therapeutic treatment may be added prior to, simultaneously with, or after the method or composition used to reduce the biofilm, and may be included within the same formulation or as a separate formulation.
[0242] Antibodies and their derivatives The present disclosure also provides antibodies that bind and / or specifically recognize a modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S disclosed herein.
[0243] It is recognized that among the equivalents to the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S of modified high mobility group box 1. For modified high mobility group-box 2, the corresponding cysteine residues are found at positions 23, 45, and 106; for modified high mobility group-box 3, the corresponding cysteine residues are found at positions 23, 45, and 104; and for modified high mobility group-box 4, the corresponding cysteine residues are found at positions 45, 104, 164, and 178. Accordingly, Applicants believe that the antibody aspects disclosed with respect to a modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S are equally applicable to the aforementioned high mobility group-box species having one or more cysteine to serine substitutions at the referenced positions (e.g., a modified high mobility group-box 2 containing one or more substitutions selected from the group of C23S, C45S, and C106S; a modified high mobility group-box 3 containing one or more substitutions selected from the group of C23S, C45S, and C104S; and a modified high mobility group-box 4 containing one or more substitutions selected from the group of C45S, C104S, C164S, and C178S).
[0244] The antibody may be any of the various antibodies described herein, non-limiting examples of which include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, human antibodies, veneered antibodies, diabodies, humanized antibodies, antibody derivatives, recombinant humanized antibodies, or derivatives or fragments of each of these. In one aspect, the fragment comprises, or alternatively consists essentially of, or even further consists of the CDRs of the antibody, examples of which are provided herein. In one aspect, the antibody is detectably labeled or further comprises a detectable label conjugated to the antibody. Also provided is a hybridoma cell line that produces the monoclonal antibodies disclosed herein. Further provided herein are compositions that comprise, or alternatively consist essentially of, or even further consist of one or more of the above embodiments. Further provided are polynucleotides encoding the amino acid sequences of the antibodies and fragments, and methods for recombinantly producing or chemically synthesizing the antibody polypeptides and fragments thereof. The antibody polypeptides can be produced in eukaryotic or prokaryotic cells, or by other methods known in the art and described herein.
[0245] Antibodies can also be produced using conventional techniques known in the art and well documented in the literature. There are several methodologies for the production of polyclonal antibodies. For example, polyclonal antibodies are typically produced by immunizing a suitable mammal, including but not limited to chickens, goats, guinea pigs, hamsters, horses, mice, rats, and rabbits. An antigen is injected into the mammal to induce B lymphocytes to produce immunoglobulins specific to the antigen. Immunoglobulins can be purified from the serum of the mammal. Variations on this methodology include modification of adjuvants, route and site of administration, injection volume per site, and number of sites per animal for optimal production and humane handling of the animals. For example, adjuvants can typically be used to improve or enhance the immune response to an antigen. Most adjuvants provide an injection site antigen depot that allows stow release of the antigen to the draining lymph nodes. Other adjuvants include surfactants and immunostimulatory molecules that facilitate the concentration of protein antigen molecules over a large surface area. Non-limiting examples of adjuvants for polyclonal antibody production include Freund's adjuvant, Ribi adjuvant system, and Titermax.Polyclonal antibody can be produced using methods known in the art, some of which are described in U.S. Patent Nos. 7,279,559; 7,119,179; 7,060,800; 6,709,659; 6,656,746; 6,322,788; 5,686,073; and 5,670,153.
[0246] Monoclonal antibodies may be produced using conventional hybridoma technology, which is known in the art and fully described in the literature. For example, hybridomas may be produced using a suitable immortalized cell line (e.g., a myeloma cell line (e.g., Sp2 / 0, Sp2 / 0-AG14, NSO, NS1, NS2, AE-1, L.5, P3X63Ag8,653, Sp2 SA3, Sp2 MAI, Sp2 SS1, Sp2 SA5, U397, MIA 144, ACT IV, MOLT4, DA-1, JURKAT, WEHI, K-562, COS, RAJI, NIH 313, HL-60, MLA 144, NAMAIWA, NEURO, etc.) 2A, CHO, PerC.6, YB2 / O, etc.), or heteromyeloma, its fusion products, or any cells or fusion cells derived therefrom, or any other suitable cell line as known in the art (see the following web addresses, e.g., atcc.org, lifetech.com (last accessed November 26, 2007)), and antibody producing cells (e.g., but not limited to, isolated or cloned spleen, peripheral blood, lymph, tonsil, or other immune or B cell containing cells), or heavy or light chain producing cells. The antibody may be produced by fusing with any other cell expressing the constant or variable region or framework or CDR sequences of the chain (either as endogenous or heterologous nucleic acid, recombinant or endogenous, viral, bacterial, algal, prokaryotic, amphibian, insect, reptilian, fish, mammalian, rodent, equine, ovine, caprine, ovine, primate, eukaryotic, genomic DNA, cDNA, rDNA, mitochondrial DNA or RNA, chloroplast DNA or RNA, hnRNA, mRNA, tRNA, single-stranded, double-stranded or triple-stranded, hybridized, etc., or any combination thereof). Antibody-producing cells may also be obtained from peripheral blood, or, in certain embodiments, from the spleen or lymph nodes of humans or other suitable animals that have been immunized with the antigen of interest.Any suitable host cell may also be used to express heterologous or endogenous nucleic acid encoding the antibodies, specific fragments or variants thereof, of the present disclosure. Fused cells (hybridomas) or recombinant cells may be isolated using selective culture conditions or other suitable known methods and cloned by limiting dilution or cell sorting, or other known methods.
[0247] Other suitable methods of generating or isolating antibodies of the required specificity may be used, including, but not limited to, recombinant antibodies selected from peptide or protein libraries (e.g., but not limited to, bacteriophage, ribosome, oligonucleotide, cDNA, etc.), display libraries; for example, as available from various commercial suppliers (e.g., MorphoSys (Martinsreid / Planegg, Del.), BioInvent (Lund, Sweden), Affitech (Oslo, Norway)) using methods known in the art. Methods known in the art are described in the patent literature, some of which include U.S. Patent Nos. 4,704,692; 5,723,323; 5,763,192; 5,814,476; 5,817,483; 5,824,514; and 5,976,862. An alternative method relies on immunizing transgenic animals capable of producing a repertoire of human antibodies (e.g., SCID mice, Nguyen et al. (1977) Microbiol. Immunol. 41:901-907 (1997); Sandhu et al. (1996) Crit. Rev. Biotechnol. 16:95-118; Eren et al. (1998) Mumma 93:154-161), as known in the art and / or described herein.Such techniques include, but are not limited to, ribosome display (e.g., Wanes et al. (1997) Proc. Natl. Acad. Sci. USA, 94:4937-4942; Hanes et al. (1998) Proc. Natl. Acad. Sci. USA 95:14130-14135); single cell antibody generation techniques (e.g., selected lymphocyte antibody method ("SLAM") (U.S. Patent No. 5,627,052; Wen et al., (1987) J. Immunol 17:887-892; Babcook et al. (1996) Proc. Natl. Acad. Sci. USA 93:7843-7848); gel microdrop and flow cytometry (Powell et al. (1990) Biotechnol. 8:333-337; One Cell System (Cambridge, Mass.); Gray et al. (1995) J. Imm. Meth. 182:155-163; and Kenny et al., (1995) Bio. Technol. 13:787-790); B cell selection (Steenbakkers et al. (1994) Molec. Biol. Reports 19:125-134).
[0248] Antibody derivatives of the present disclosure can also be prepared by delivering a polynucleotide encoding an antibody or fragment thereof disclosed herein to a suitable host, such as to provide a transgenic animal or mammal (e.g., goat, cow, horse, sheep, etc.) that produces such antibodies in its milk. These methods are known in the art and described, for example, in U.S. Patent Nos. 5,827,690; 5,849,992; 4,873,316; 5,849,992; 5,994,616; 5,565,362; and 5,304,489.
[0249] The term "antibody derivatives" includes post-translational modifications to the linear polypeptide sequence of the antibody or fragment thereof. For example, U.S. Patent No. 6,602,684 B1 describes methods for the production of modified glycol forms of antibodies (including complete antibody molecules, antibody fragments, or fusion proteins containing a region equivalent to the Fc region of an immunoglobulin and having enhanced Fc-mediated cytotoxicity, including the glycoproteins so produced).
[0250] The antibodies disclosed herein also include derivatives that are modified by the covalent attachment of any type of molecule to the antibody, such that the covalent attachment does not prevent the antibody from generating an anti-idiotypic response. Antibody derivatives include, but are not limited to, antibodies modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, and the like. Additionally, the derivatives may contain one or more non-classical amino acids.
[0251] Antibody derivatives can also be prepared by delivering the polynucleotides disclosed herein to provide transgenic plants and cultured plant cells (including, but not limited to, tobacco, corn, and duckweed) that produce such antibodies, specific portions of the variants in plant parts or cells cultured therefrom. For example, Cramer et al. (1999) Curr. Top. Microbol. Immunol. 240:95-118 and references cited therein describe the production of transgenic tobacco leaves that express large amounts of recombinant proteins, for example, using inducible promoters. Transgenic corn has been used to express mammalian proteins with biological activity equivalent to those produced in other recombinant systems or purified from natural sources at commercial production levels. See, for example, Hood et al. (1999) Adv. Exp. Med. Biol. 464:127-147 and references cited therein. Antibody derivatives have also been produced in large quantities from transgenic plant seeds, including tobacco seeds and potato tubers, that contain antibody fragments, such as single-chain antibodies (scFv's). See, for example, Conrad et al. (1998) Plant Mol. Biol. 38:101-109 and references cited therein. Thus, antibodies can also be produced using transgenic plants, in accordance with known methods.
[0252] Antibody derivatives can also be generated by adding exogenous sequences, for example, to modify immunogenicity or to reduce, enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any other suitable property. Generally, some or all of the non-human or human CDR sequences are maintained while the non-human sequences of the variable and constant regions are replaced with human or other amino acids.
[0253] In general, the CDR residues are directly, and for the most part substantially, involved in influencing antigen binding. Antibody humanization or engineering can be carried out using any known method, including, but not limited to, those described in U.S. Pat. Nos. 5,723,323; 5,976,862; 5,824,514; 5,817,483; 5,814,476; 5,763,192; 5,723,323; 5,766,886; 5,714,352; 6,204,023; 6,180,370; 5,693,762; 5,530,101; 5,585,089; 5,225,539; and 4,816,567.
[0254] The general structure of an antibody is known in the art and will only be briefly summarized here. An immunoglobulin monomer comprises two heavy chains and two light chains connected by disulfide bonds. Each heavy chain is paired with one of the light chains directly linked via disulfide bonds. Each heavy chain comprises a constant region (which varies depending on the antibody's isotype) and a variable region. The variable region comprises three hypervariable regions (or complementarity determining regions), which are called CDRH1, CDRH2 and CDRH3 and are supported within framework regions. Each light chain comprises a constant region and a variable region, which comprises three hypervariable regions (called CDRL1, CDRL2 and CDRL3) supported by framework regions in a manner similar to the variable region of the heavy chain.
[0255] The hypervariable regions of each pair of heavy and light chains cooperate with each other to provide an antigen-binding site that can bind a target antigen. The binding specificity of a pair of heavy and light chains is defined by the sequences of CDR1, CDR2 and CDR3 of the heavy and light chains. Thus, once a set of CDR sequences that produces a particular binding specificity (i.e., the sequences of CDR1, CDR2 and CDR3 of the heavy and light chains) is determined, that set of CDR sequences can be inserted into any suitable position in any other antibody framework region linked to any antibody constant region to provide a different antibody with the same antigen-binding specificity in principle.
[0256] In some of the aspects of the antibodies provided herein, the antibodies bind to DNABII protein at least 10 -4 M, 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, or 10 -12 Dissociation constant (K D ) to join them.
[0257] In some aspects of the antibodies provided herein, the antibody is a soluble Fab.
[0258] In some aspects of the antibodies provided herein, the HC and LC variable domain sequences are components of the same polypeptide chain. In some aspects of the antibodies provided herein, the HC and LC variable domain sequences are components of different polypeptide chains.
[0259] In some aspects of the antibodies provided herein, the antibodies are full-length antibodies.
[0260] In some aspects of the antibodies provided herein, the antibodies are monoclonal antibodies.
[0261] In some aspects of the antibodies provided herein, the antibodies are chimeric or humanized.
[0262] In some of the aspects of the antibodies provided herein, the antibodies may be Fab, F(ab)'2, Fab', scF v , and F v Selected from the group consisting of
[0263] In some of the antibody aspects provided herein, the antibody comprises an Fc domain.In some of the antibody aspects provided herein, the antibody is a rabbit antibody.In some of the antibody aspects provided herein, the antibody is a human or humanized antibody, or is non-immunogenic in humans.
[0264] In some aspects of the antibodies provided herein, the antibodies comprise a human antibody framework region.
[0265] In other aspects, one or more amino acid residues in the CDRs of the antibodies provided herein are replaced with another amino acid. The substitutions can be "conservative" in the sense that they are substitutions within the same family of amino acids. The naturally occurring amino acids can be divided into the following four families, and conservative substitutions occur within those families:
[0266] 1) Amino acids with basic side chains: lysine, arginine, histidine.
[0267] 2) Amino acids with acidic side chains: aspartic acid, glutamic acid.
[0268] 3) Amino acids with uncharged polar side chains: asparagine, glutamine, serine, threonine, tyrosine.
[0269] 4) Amino acids with non-polar side chains: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, cysteine.
[0270] In another aspect, one or more amino acid residues are added to or deleted from one or more CDRs of the antibody, such additions or deletions occurring at the N-terminus or C-terminus of the CDR, or at a position within the CDR.
[0271] By varying the amino acid sequence of the CDRs of an antibody by adding, deleting or substituting amino acids, various effects can be obtained (eg, increased binding affinity for the target antigen).
[0272] It should be appreciated that antibodies of the disclosure containing such altered CDR sequences will still bind with a similar specificity and sensitivity profile as the disclosed antibodies, which can be tested through binding assays.
[0273] The constant region of the antibody can also be varied. For example, the antibody can be provided with an Fc region of any isotype: IgA (IgA1, IgA2), IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4) or IgM. Non-limiting examples of constant region sequences include:
[0274] Human IgD constant region, Uniprot: P01880 SEQ ID NO:37 [ka]
[0275] Human IgG1 constant region, Uniprot: P01857 SEQ ID NO:38 [ka] [ka]
[0276] Human IgG2 constant region, Uniprot: P01859 SEQ ID NO:39 [ka]
[0277] Human IgG3 constant region, Uniprot: P01860 SEQ ID NO:40 [ka]
[0278] Human IgM constant region, Uniprot: P01871 SEQ ID NO:41 [ka]
[0279] Human IgG4 constant region, Uniprot: P01861 SEQ ID NO:42 [ka] [ka]
[0280] Human IgA1 constant region, Uniprot: P01876 SEQ ID NO:43 [ka]
[0281] Human IgA2 constant region, Uniprot: P01877 SEQ ID NO:44 [ka]
[0282] Human Igκ constant region, Uniprot: P01834 SEQ ID NO:45 [ka]
[0283] In some aspects of the antibodies provided herein, the antibodies contain structural modifications to promote rapid binding and cellular uptake and / or slow release. In some aspects, the DNABII antibodies contain deletions in the CH2 constant heavy chain region of the antibodies to promote rapid binding and cellular uptake and / or slow release. In some aspects, Fab fragments are used to promote rapid binding and cellular uptake and / or slow release. In some aspects, F(ab)'2 fragments are used to promote rapid binding and cellular uptake and / or slow release.
[0284] The antibodies, fragments and equivalents thereof can be combined with carriers (eg, pharma- ceutically acceptable carriers) or other agents to provide a formulation for use and / or storage.
[0285] The chimeric, humanized or primatized antibody of the present disclosure can be prepared based on the sequence of a reference monoclonal antibody prepared using standard molecular biology techniques. The DNA encoding heavy and light chain immunoglobulins can be obtained from the hybridoma of interest and can be engineered to include non-reference (e.g., human) immunoglobulin sequences using standard molecular biology techniques. For example, to create a chimeric antibody, mouse variable regions can be linked to human constant regions using methods known in the art (U.S. Patent No. 4,816,567). To create a humanized antibody, mouse CDR regions can be inserted into a human framework using methods known in the art (U.S. Patent No. 5,225,539 and U.S. Patent No. 5,530,101; U.S. Patent No. 5,585,089; U.S. Patent No. 5,693,762 and U.S. Patent No. 6,180,370). Similarly, to create a primatized antibody, murine CDR regions can be inserted into a primate framework using methods known in the art (WO 93 / 02108 and WO 99 / 55369).
[0286] Methods for producing partially to fully human antibodies are known in the art, and any such technique may be used. According to one embodiment, fully human antibody sequences are produced in transgenic mice engineered to express human heavy and light chain antibody genes. Numerous strains of such transgenic mice have been produced, which are capable of producing a variety of antibody classes. B cells from the transgenic mice producing the desired antibody can be fused to generate hybridoma cell lines for continued production of the desired antibody (see, e.g., Russell et al. (2000) Infection and Immunity April 2000:1820-1826; Gallo et al. (2000) European J. of Immun. 30:534-540; Green (1999) J. of Immun. Methods 231:11-23; Yang et al. (1999A) J. of Leukocyte Biology 66:401-410; Yang (1999B) Cancer Research 59(6):1236-1243; Jakobovits (1998) Advanced Drug Reviews 31:33-42; Green and Jakobovits (1998) J. Exp. Med. 188(3):483-495; Jakobovits (1998) Exp. Opin. Invest. Drugs 7(4):607-614; Tsuda et al. (1997) Genomics 42:413-421; Sherman-Gold (1997) Genetic Engineering News 17(14); Mendez et al. (1997) Nature Genetics 15:146-156; Jakobovits (1996) Weir's Handbook of Experimental Immunology, The Integrated Immune System Vol. IV, 194.1-194.7; Jakobovits (1995) Current Opinion in Biotechnology 6:561-566; Mendez et al.(1995) Genomics 26:294-307; Jakobovits (1994) Current Biology 4(8):761-763; Arbones et al. (1994) Immunity 1(4):247-260; Jakobovits (1993) Nature 362(6417):255-258; Jakobovits et al. (1993) Proc. Natl. Acad. Sci. USA 90(6):2551-2555; and U.S. Patent No. 6,075,181.
[0287] The antibodies disclosed herein can also be modified to create chimeric antibodies, in which the various domains of the heavy and light chains of the antibody are encoded by DNA from more than one species. See, for example, U.S. Patent No. 4,816,567.
[0288] Alternatively, the antibodies disclosed herein can also be modified to create veneered antibodies. Veneered antibodies are those in which the outer amino acid residues of an antibody of one species are replaced or "veneered" in a judicious manner with the outer amino acid residues of a second species, so that the antibody of the first species is not immunogenic in the second species, thereby reducing the immunogenicity of the antibody. Since the antigenicity of a protein depends primarily on the nature of its surface, the immunogenicity of an antibody can be reduced by replacing exposed residues that are different from those normally found in antibodies of another mammalian species. This judicious replacement of outer residues should have little or no effect on the inner domains or on interdomain contacts. Thus, the ligand binding properties should not be affected as a result of the qualitative changes limited to the variable region framework residues. The process is referred to as "veneering", because only the outer surface or skin of the antibody is qualitatively altered, while the supporting residues remain undisturbed.
[0289] The procedure for "veneering" utilizes available sequence data of human antibody variable domains compiled by Kabat et al. (1987) Sequences of Proteins of Immunological interest, 4th ed., Bethesda, Md., National Institutes of Health, updates to this database, as well as other accessible U.S. and foreign databases (both nucleic acid and protein). Non-limiting examples of methods used to generate veneered antibodies include those described in EP 519596; U.S. Patent No. 6,797,492; and Padlan et al. (1991) Mol. Immunol. 28(4-5):489-498.
[0290] The term "antibody derivative" also includes "diabodies," which are small antibody fragments having two antigen-binding sites, in which the fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (see, e.g., EP 404,097; WO 93 / 11161; and Hollinger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with complementary domains on another chain, creating two antigen-binding sites (see also U.S. Pat. No. 6,632,926 (Chen et al.), which discloses one or more amino acid residues inserted into a hypervariable region of a parent antibody and antibody variants having binding affinity for a target antigen that is at least about two-fold stronger than the binding affinity of the parent antibody for that antigen).
[0291] The term "antibody derivatives" further includes: engineered antibody molecules, fragments and single domains (e.g., scFv, dAbs, nanobodies, minibodies, Unibodies, and Affibodies as well as Hudson (2005) Nature Biotech 23(9):1126-36; U.S. Patent Application Publication US 2006 / 0211088; PCT Publication WO 2007 / 059782; U.S. Patent No. 5,831,012.
[0292] The term "antibody derivative" further includes "linear antibodies." Procedures for making linear antibodies are known in the art and are described in Zapata et al. (1995) Protein Eng. 8(10):1057-1062. Briefly, these antibodies consist of a pair of tandem Ed segments (V H -C H 1-VH-C H 1). Linear antibodies can be bispecific or monospecific.
[0293] The antibodies disclosed herein can be recovered and purified from recombinant cell culture by known methods, including, but not limited to, protein A purification, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. High performance liquid chromatography ("HPLC") can also be used for purification.
[0294] The antibodies of the present disclosure include naturally purified products, products of chemical synthesis procedures, and products produced by recombinant technology from eukaryotic hosts (including, for example, yeast, higher plants, insect and mammalian cells), or alternatively from prokaryotic hosts as described above.Many antibody production systems are described in Birch & Radner (2006) Adv. Drug Delivery Rev. 58:671-685.
[0295] If the antibody being tested binds to a protein or polypeptide, the antibody being tested and the antibody provided by the present disclosure are equivalent. It is also possible to determine without undue experimentation whether an antibody has the same specificity as the antibody disclosed herein by determining whether the antibody being tested prevents the antibody disclosed herein from binding to the protein or polypeptide with which it is normally reactive. If the antibody being tested competes with the antibody disclosed herein, as shown by a decrease in binding by the monoclonal antibody disclosed herein, the two antibodies are likely to bind to the same or closely related epitopes. Alternatively, it is possible to preincubate the antibody disclosed herein with the protein with which it is normally reactive, and determine whether the antibody being tested is inhibited in its ability to bind to the antigen. If the antibody being tested is inhibited, it likely has the same or closely related epitopic specificity as the antibody disclosed herein.
[0296] The term "antibody" is also intended to include antibodies of all immunoglobulin isotypes and subclasses. A specific isotype of monoclonal antibody can be prepared either directly by selection from the initial fusion or secondarily from parent hybridomas secreting monoclonal antibodies of different isotypes by using sib selection techniques to isolate class-switched variants using the procedures described in Steplewski et al. (1985) Proc. Natl. Acad. Sci. USA 82:8653 or Spira et al. (1984) J. Immunol. Methods 74:307. Alternatively, recombinant DNA techniques can be used.
[0297] Isolation of other monoclonal antibodies having the specificity of the monoclonal antibodies described herein can also be accomplished by one of skill in the art by generating anti-idiotypic antibodies. Herlyn et al. (1986) Science 232:100. Anti-idiotypic antibodies are antibodies that recognize unique determinants present on the monoclonal antibody of interest.
[0298] In some aspects disclosed herein, it is useful to detectably or therapeutically label the antibody. Suitable labels are described above. Methods for conjugating antibodies to these agents are known in the art. For illustrative purposes only, the antibody can be labeled with a detectable moiety (e.g., radioactive atom, chromophore, fluorophore, etc.). Such labeled antibodies can be used for diagnostic techniques either in vivo or in isolated test samples.
[0299] Coupling of an antibody to a low molecular weight hapten can increase the sensitivity of the antibody in an assay. The hapten can then be specifically detected by a second reaction. For example, it is common to use haptens such as biotin, which reacts with avidin, or dinitrophenol, pyridoxal, and fluorescein, which can react with specific anti-hapten antibodies. See Harlow and Lane (1988), supra.
[0300] The variable regions of the antibodies of the present disclosure may be modified by mutating amino acid residues in the CDR 1, CDR 2 and / or CDR 3 regions of VH and / or VL to improve one or more binding properties (e.g., affinity) of the antibody. Mutations may be introduced by site-directed or PCR-mediated mutagenesis, and the effect on antibody binding or other functional properties of interest may be evaluated in suitable in vitro or in vivo assays. In certain embodiments, conservative modifications are introduced, typically no more than one, two, three, four or five residues in the CDR regions are altered. The mutations may be amino acid substitutions, additions or deletions.
[0301] Framework modifications can be made to an antibody to reduce immunogenicity, e.g., by "backmutating" one or more framework residues to their corresponding germline sequence.
[0302] Additionally, the antibodies disclosed herein can be engineered to contain modifications in the Fc region to alter one or more functional properties of the antibody (e.g., serum half-life, complement binding, Fc receptor binding, and / or antigen-dependent cellular cytotoxicity). Such modifications include, but are not limited to, altering the number of cysteine residues in the hinge region to facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody (U.S. Patent No. 5,677,425) and altering the number of amino acid mutations in the Fc hinge region to decrease the biological half-life of the antibody (U.S. Patent No. 6,165,745).
[0303] Furthermore, the antibody disclosed herein can be chemically modified. The glycosylation of the antibody can be altered by modifying one or more glycosylation sites in the antibody sequence, for example, to increase the affinity of the antibody to the antigen (US Pat. Nos. 5,714,350 and 6,350,861). Alternatively, to increase antibody-dependent cell-mediated cytotoxicity, hypofucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bisected GlcNac structures can be obtained by expressing the antibody in a host cell with altered glycosylation machinery (Shields et al., 2002 J. Biol. Chem. 277:26733-26740; Umana et al., 1999 Nat. Biotech. 17:176-180).
[0304] The antibodies disclosed herein can be pegylated to increase biological half-life by reacting the antibody or fragment thereof with polyethylene glycol (PEG) or a reactive ester or aldehyde derivative of PEG under conditions in which one or more PEG groups are attached to the antibody or antibody fragment. Antibody pegylation can be carried out by an acylation reaction or an alkylation reaction with a reactive PEG molecule (or a similar reactive water-soluble polymer). As used herein, the term "polyethylene glycol" is intended to encompass any of the forms of PEG that have been used to derivatize other proteins (e.g., mono (C1-C10) alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide). The antibody to be pegylated can be an aglycosylated antibody. Methods for pegylation of proteins are known in the art and can be applied to the antibodies disclosed herein (EP 0154316 and EP 0401384).
[0305] Additionally, antibodies can be chemically modified by conjugating or fusing the antigen-binding region of the antibody to a serum protein (e.g., human serum albumin) to increase the half-life of the resulting molecule. Such approaches are described, for example, in EP 0322094 and EP 0486525.
[0306] The antibody or fragment thereof of the present disclosure may be conjugated to a diagnostic agent and used diagnostically, for example, to monitor the onset or progression of a disease and to determine the effectiveness of a given treatment regimen. Examples of diagnostic agents include enzymes, prosthetic groups, fluorescent substances, luminescent substances, bioluminescent substances, radioactive substances, positron-emitting metals, and non-radioactive protonic metal ions using various positron emission tomography techniques. The detectable substance may be coupled or conjugated to the antibody or fragment thereof either directly, or indirectly through a linker, using techniques known in the art. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase. Examples of suitable prosthetic group complexes include streptavidin / biotin and avidin / biotin. Examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin. Examples of luminescent materials include luminol. Examples of bioluminescent materials include luciferase, luciferin, and aequorin. Examples of suitable radioactive materials include: 125 I, 131I, Indium-111, Lutetium-171, Bismuth-212, Bismuth-213, Astatine-211, Copper-62, Copper-64, Copper-67, Yttrium-90, Iodine-125, Iodine-131, Phosphorus-32, Phosphorus-33, Scandium-47, Silver-111, Gallium-67, Praseodymium-142, Samarium-153, Terbium-161, Dysprosium-166, Holmium-1 66, rhenium-186, rhenium-188, rhenium-189, lead-212, radium-223, actinium-225, iron-59, selenium-75, arsenic-77, strontium-89, molybdenum-99, rhodium-1105, palladium-109, praseodymium-143, promethium-149, erbium-169, iridium-194, gold-198, gold-199, and lead-211. Monoclonal antibodies may be indirectly conjugated to radioactive metal ions through the use of a bifunctional chelating agent covalently linked to the antibody. Chelators can be attached through the amino groups of amino acid residues (Meares et al., 1984 Anal. Biochem. 142: 68-78); sulfhydral groups (Koyama 1994 Chem. Abstr. 120: 217262t) and carbohydrate groups (Rodwell et al. 1986 PNAS USA 83: 2632-2636; Quadri et al. 1993 Nucl. Med. Biol. 20: 559-570).
[0307] Additionally, the antibodies or fragments thereof of the present disclosure may be conjugated to a therapeutic agent. Suitable therapeutic agents include: taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, and the like. dione), mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil, decarbazine, hydroxyurea, asparaginase, gemcitabine, cladribine), alkylating agents (e.g., mechlorethamine, thiotepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozocin, dacarbazine (DTIC), procarbazine, mitomycin C, cisplatin and other platinum derivatives (e.g., carboplatin ), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, daunorubicin (formerly daunomycin), doxorubicin, idarubicin, mithramycin, mitomycin, mitoxantrone, plicamycin, anthramycin (AMC)), diphtheria toxin and related molecules (e.g., diphtheria A chain and its active fragments and hybrid molecules), ricin toxin (e.g., ricin A or deglycosylated ricin A chain toxin), cholera toxin, Shiga-like toxins (SLT-I, SLT-II, SLT-IIV), LT toxin, C3 isotopes, Shiga toxin, pertussis toxin, tetanus toxin, soybean Bowman-Birk protease inhibitor, Pseudomonas exotoxin, allorin (), saporin, modeccin, geranin, abrin A chain, modeccin A chain, α-sarcin, Aleurites fordii protein, dianthin protein, Phytolaccaamericana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitors, curcin, crotin, Sapaonaria officinalis inhibitors, gelonin, mitogellin, restrietocin, phenomycin, enomycin toxins and mixed toxins.
[0308] Further suitable conjugated molecules include ribonucleases (RNases), DNases, antisense nucleic acids, inhibitory RNA molecules (e.g., siRNA molecules), immunostimulatory nucleic acids, aptamers, ribozymes, triplex-forming molecules, and external guide sequences. Aptamers are small nucleic acids ranging from 15 to 50 bases in length that fold into defined secondary and tertiary structures (e.g., stem-loops or G-quartets) and can bind small molecules (e.g., ATP (U.S. Pat. No. 5,631,146) and theophylline (U.S. Pat. No. 5,580,737)) and large molecules (e.g., reverse transcriptase (U.S. Pat. No. 5,786,462) and thrombin (U.S. Pat. No. 5,543,293)). Ribozymes are nucleic acid molecules that can catalyze chemical reactions, either intramolecularly or intermolecularly. Ribozymes typically cleave nucleic acid substrates through recognition and binding with subsequent cleavage of their target substrates. Triplex-forming functional nucleic acid molecules can interact with double-stranded or single-stranded nucleic acid by forming triplexes, where the three strands of DNA form a complex that depends on both Watson-Crick and Hoogsteen base pairing.Triplex molecules can bind to target regions with high affinity and specificity.Suitable conjugation molecules can further include any protein that binds to DNA, provided that it does not create or stabilize biofilm structure; it is envisioned that at least a partial set of such proteins can promote the kinetics of binding to the agents disclosed herein.
[0309] Functional nucleic acid molecules can act as effectors, inhibitors, regulators, and stimulators of a specific activity possessed by the target molecule, or the functional nucleic acid molecule can have novel activity independent of any other molecule.
[0310] The therapeutic agent can be linked to the antibody directly or indirectly using any of the numerous available methods. For example, the agent can be attached to the hinge region of the reduced antibody component via disulfide bond formation, using a crosslinker such as N-succinyl 3-(2-pyridyldithio)propionate (SPDP), or via a carbohydrate moiety in the Fc region of the antibody (Yu et al. 1994 Int. J. Cancer 56: 244; Upeslacis et al., "Modification of Antibodies by Chemical Methods", in Monoclonal antibodies: principles and applications, Birch et al. (eds.), pp. 187-230 (Wiley-Liss, Inc. 1995); Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies", in Monoclonal antibodies: Production, engineering and clinical application, Ritter et al. (eds.), pp. 60-84 (Cambridge University Press 1995)).
[0311] Techniques for conjugating therapeutic agents to antibodies are well known (Amon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibodies", in in Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates" 1982 Immunol. Rev. 62:119-58).
[0312] The antibodies or antigen-binding regions thereof disclosed herein can be linked to another functional molecule (e.g., another antibody or ligand) to generate bispecific or multispecific molecules that bind to at least two or more different binding sites or target molecules. Linking the antibody to one or more other binding molecules (e.g., another antibody, antibody fragment, peptide, or binding mimetic) can be performed, for example, by chemical coupling, genetic fusion, or non-covalent association. Multispecific molecules can further include a third binding specificity in addition to the first and second target epitopes.
[0313] Bispecific and multispecific molecules can be prepared using methods known in the art. For example, each binding unit of the hi-specific molecule can be produced separately and then conjugated to each other. When the binding molecule is a protein or peptide, various coupling or cross-linking agents can be used for covalent conjugation. Examples of cross-linking agents include: protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-I-carboxylate (sulfo-SMCC) (Karpovsky et al., 1984 J. Exp. Med. 160:1686; Liu et al., 1985 Proc. Natl. Acad. Sci. USA 82:8648). When the binding molecule is an antibody, they can be conjugated by sulfhydryl bonds at the C-terminal hinge regions of the two heavy chains.
[0314] The antibodies disclosed herein can also be attached to solid supports, which are particularly useful for immunoassays or purification of their target antigens. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
[0315] The antibody can also be bound to many different carriers. Thus, the present disclosure also provides a composition comprising the antibody and another substance (active or inactive). Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylase, natural and modified cellulose, polyacrylamide, agarose, and magnetite. The nature of the carrier can be either soluble or insoluble for the purpose disclosed herein. Those skilled in the art will know of other suitable carriers for binding monoclonal antibodies, or can ascertain them using routine experimentation.
[0316] The antibodies disclosed herein can be used to purify the polypeptides disclosed herein and to identify biologically equivalent polypeptides and / or polynucleotides.They can also be used to identify agents that modify the function of the polypeptides disclosed herein.These antibodies include polyclonal antisera, monoclonal antibodies, and various reagents derived from these preparations that are familiar to those skilled in the art and described above.
[0317] Antibodies that neutralize the activity of the proteins encoded by the identified genes can also be used in vivo and in vitro to demonstrate function by adding such neutralizing antibodies to in vivo and in vitro test systems. They are also useful as drugs to modulate the activity of the polypeptides disclosed herein.
[0318] Various antibody preparations can also be used in analytical methods such as ELISA assays or Western blots to show the expression of the proteins encoded by the identified genes by testing cells in vitro or in vivo.Fragments of such proteins generated by protease degradation during metabolism can also be identified by using appropriate polyclonal antisera with samples derived from experimental samples.
[0319] Further, in some embodiments, the antibodies disclosed herein may be used to visualize and / or detect biofilms. In such embodiments, the antibodies may be detectably labeled, for example, with a radioisotope, an enzyme that produces a detectable product, a fluorescent protein, or may be conjugated to other moieties, such as, for example, a member of a specific binding pair, such as, for example, biotin (a member of the biotin-avidin specific binding pair). The detectably labeled antibodies may then be introduced into a sample suspected of being colonized with a biofilm and visualized and / or detected through microscopy or other methods known to detect the associated label, such as, for example, spectroscopy, cytometry, or other common techniques. The conjugated or unlabeled antibodies may similarly be identified through known analytical methods that target the conjugated moiety or antibody, respectively. For example, in some embodiments, detectably labeled secondary antibodies specific for the isotype of the antibodies disclosed herein may be used in the visualization and / or detection of biofilms.
[0320] kit Kits containing the necessary agents and instructions for carrying out the in vitro and in vivo methods as described herein are also claimed.Thus, the present invention provides kits for carrying out these methods, which may contain the modified high mobility group-box 1 domains disclosed herein and instructions for carrying out the methods of the present invention (e.g., collecting tissue and / or performing screening and / or analyzing results and / or administering an effective amount thereof as defined herein).These may be used alone or in combination with other suitable antimicrobial agents.
[0321] In one embodiment, the present disclosure provides a kit comprising a polypeptide comprising a modified high mobility group-box 1 domain comprising one or more substitutions selected from the group of C23S, C45S, and C106S, and instructions for use in disrupting biofilms or inhibiting, preventing, or treating biofilm-producing microbial infections. Examples of modified high mobility group-box 1 domains comprising one or more substitutions selected from the group of C23S, C45S, and C106S are described above. In some embodiments, the modified high mobility group-box 1 domain comprises the substitution C45S. In some embodiments, the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S. In one embodiment, the kit further comprises one or more of an adjuvant, an antigenic peptide, or an antimicrobial agent. In yet another embodiment, the kit further comprises a carrier selected from the group of a liquid carrier, a pharma- ceutically acceptable carrier, a solid phase carrier, a pharma- ceutically acceptable carrier, an implant, a stent, a paste, a gel, a dental implant, or a medical implant.
[0322] It is recognized that among the equivalents to the modified high mobility group-box 1 domain are modified high mobility group-box 2, modified high mobility group-box 3, and modified high mobility group-box 4, which contain cysteine to serine substitutions at one or more amino acid positions corresponding to C23S, C45S, and C106S of modified high mobility group box 1. For modified high mobility group-box 2, the corresponding cysteine residues are found at positions 23, 45, and 106; for modified high mobility group-box 3, the corresponding cysteine residues are found at positions 23, 45, and 104; and for modified high mobility group-box 4, the corresponding cysteine residues are found at positions 45, 104, 164, and 178. Accordingly, Applicants believe that the kit aspects disclosed with respect to modified high mobility group-box 1 containing one or more substitutions selected from the group of C23S, C45S, and C106S are equally applicable to the aforementioned high mobility group-box species having one or more cysteine to serine substitutions at the referenced positions (e.g., modified high mobility group-box 2 containing one or more substitutions selected from the group of C23S, C45S, and C106S; modified high mobility group-box 3 containing one or more substitutions selected from the group of C23S, C45S, and C104S; and modified high mobility group-box 4 containing one or more substitutions selected from the group of C45S, C104S, C164S, and C178S).
[0323] The following examples are intended to illustrate, but not limit, the present invention. EXAMPLES
[0324] Example 1 – mHMGBI(C45S) Study Applicant added 0.1 μg / ml, 1 μg / ml and 5 μg / ml of HMGB1 to biofilms formed by uropathogenic E. coli UTI89 at the time of inoculation and at 24 hours. When added at the time of inoculation and at 24 hours, a dose-dependent disruption of UPEC biofilms was observed. Based on this information, Applicant hereby discloses a method for inhibiting, competing or titrating the binding of deoxyribonucleic acid B II (DNABII) polypeptides to microbial DNA in a biofilm, said method comprising, alternatively consisting essentially of, or even further consisting of the step of contacting the microbial DNA in the biofilm with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain (mHMGB1) containing a C45S substitution, thereby inhibiting, competing or titrating the binding of DNABII polypeptides to the microbial DNA. The contacting step can be accomplished in vitro or in vivo. Non-limiting examples of organisms that promote or cause the biofilm include one or more of Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), acapsulated Haemophilus influenzae (NTHI), and / or Aggregatibacter actinomycetemcomitans.
[0325] Preliminary results mHMGB1(C45S) retains its anti-biofilm function in vitro against multiple human pathogens To determine the anti-biofilm function of variant HMGB1 (mHMGB1(C45S)), applicant expressed and purified human recombinant HMGB1 (rHMGB1) and recombinant variant HMGB1 (mHMGB1(C45S)) in E. coli. 24-hour in vitro biofilms formed by a number of human pathogens as shown in Table 1 were incubated with 5 μg / ml rHMGB1 or mHMGB1(C45S) for 16 hours. Enterococcus faecium biofilms were incubated with 20 μg / ml rHMGB1 or mHMGB1(C45S) for 16 hours. Biofilms were washed, stained with LIVE / DEAD® stain, and analyzed using confocal laser scanning microscopy and COMSTAT analysis. Applicants observed that mHMGB1(C45S) was effective in disrupting each of the preformed biofilms in vitro, as indicated by a significant reduction in average thickness and biomass compared to the control (Table 1). As shown in Table 1, the anti-biofilm activity of mHMGB1(C45S) was also comparable to that of rHMGB1. These data suggested that the substitution of cysteine with serine at position 45 did not qualitatively alter the anti-biofilm activity of human recombinant HMGB1.
[0326] mHMGB1(C45S) retains its antibiofilm function in vivo in two different animal models, but its inflammatory response is significantly attenuated To test the anti-biofilm function of mHMGB1(C45S) in vivo, Applicant used two different animal models. In the first model, Applicant tested the ability of rHMGB1 and mHMGB1(C45S) to clear NTHI biofilms in Applicant's well-established chinchilla model of experimental OM (Novotny et al. 2011; 2013b; Novotny et al. 2016). Applicant first established NTHI strain 86-028NP biofilms in chinchilla middle ears for 4 days. Applicant then treated the 4-day-old NTHI biofilms with two doses (days 4 and 5; 5 μg each) of rHMGB1, mHMGB1(C45S) or diluent. On day 6, animals were sacrificed and the middle ears were blindly scored for the presence of any remaining biofilm. Animals treated with diluent exhibited thick mucosal biofilms in the middle ear (FIGS. 1A-1B). Notably, rHMGB1 and mHMGB1(C45S) were highly effective in clearing the biofilm from the middle ear, as indicated by a visible bony septum (FIGS. 1A-1B). In a second model, applicants tested the ability of rHMGB1 and mHMGB1(C45S) to inhibit biofilm development of Burkholderia cenocepacia in the mouse airways. C57BL / 6 mice were inoculated with 10 7CFU of B. cenocepacia was infected intratracheally and 5 μg of rHMGB1 or mHMGB1(C45S) was added simultaneously. After 18 hours, the animals were sacrificed and bronchoalveolar lavage fluid (BAL) and lungs were collected. CFU (Figure 2A), total inflammatory infiltrate (Figure 2B), and total infiltrating neutrophils (Figure 2C) were counted in the BAL. rHMGB1 and mHMGB1(C45S) were effective in reducing bacterial load in the BAL when compared to controls (Figure 2A). rHMGB1 caused a strong inflammatory response as evidenced by an increase in total inflammatory infiltrate and neutrophils, whereas mHMGB1(C45S) showed a significantly weaker inflammatory response (Figure 2B, Figure 2C). Applicants also assessed lung injury 72 hours after infection and treatment and observed that lungs treated with rHMGB1 showed severe inflammation and an increased neutrophil response, while lungs treated with mHMGB1(C45S) were more similar to uninfected mouse lungs (Figure 2D). Finally, Applicants tested the inflammatory activity of rHMGB1 and mHMGB1(C45S) in an in vivo chemotaxis model to determine their ability to recruit neutrophils (Orlova et al. 2007; Penzo et al. 2010). C57BL / 6 mice were injected with 5 μg of either mHMGB1(C45S) or rHMGB1, or 1 ml of 4% thioglycollate. After 4 hours, mice were sacrificed and total neutrophils were quantified in the peritoneal lavage fluid. As can be seen in Figure 3, rHMGB1 induced neutrophil recruitment to the peritoneal cavity, whereas mHMGB1(C45S) did not recruit neutrophils. Collectively, these results demonstrated that mHMGB1(C45S) promoted bacterial clearance without the undesirable pro-inflammatory activity of rHMGB1. [Table 1]
[0327] HMGB1 isoforms (5 μg / ml) were added to in vitro bacterial biofilms at 24 hours. 16 hours after inoculation (total 40 hours), biofilms were washed and stained with LIVE / DEAD® and subsequently visualized using CLSM. Biofilms were analyzed by Comstat to determine the average thickness. a (AT) and biomass a (BM) was calculated.
[0328] Further experiments were performed to confirm the effects of mHMGB1(C45S) (Figures 4-7).
[0329] Example 2 – Triple Mutant HMGB1 (C23S, C45S, and C106S) and Other Variants Applicant generates triple mutant HMGB1 and other variants containing C23S, C45S, and C106S substitutions (for example, but not limited to, HMGB1 variants containing C23S alone, C23S and C45S, C23S and C106S, C45S and C106S, and C106S alone). These modified high mobility group-box 1 domains are tested for efficacy according to the same method as in Example 1. The same purpose is carried out for the HMGB2 variants, HMGB3 variants, and HMGB4 variants disclosed herein (i.e., single, double, triple, and quadruple mutants whose sequences are provided hereinabove).
[0330] Equivalent Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0331] The technology illustratively described herein may suitably be practiced in the presence of any element or limitation not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like, shall be read broadly and without limitation. Moreover, the terms and expressions used herein are used as terms of description and not as limitations, and there is no intention in the use of such terms and expressions to exclude any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the technology claimed.
[0332] Accordingly, it should be understood that the materials, methods, and examples provided herein are representative of preferred aspects and are illustrative and not intended as limitations on the scope of the technology.
[0333] The technology is described broadly and generically herein. Each of the narrower species and subgeneric groupings that fall within the scope of the generic disclosure also form part of the technology. This includes the generic description of the technology with any provisos or negative limitations that remove any subject matter from the genus, whether or not the removed material is specifically described herein.
[0334] Furthermore, when features or aspects of the technology are described in terms of a Markush group, those of skill in the art will recognize that the technology is also thereby described in terms of any individual members or subgroups of members of the Markush group.
[0335] All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety herein to the same extent as if each was individually incorporated by reference. In case of conflict, the present specification, including definitions, will control.
[0336] Other aspects are within the scope of the following claims. References Abraham, E., Arcaroli, J., Carmody, A., Wang, H., and Tracey, K.J. (2000) HMG-1 as a mediator of acute lung inflammation. J Immunol 165: 2950-4. Agnello, D., Wang, H., Yang, H., Tracey, K.J., and Ghezzi, P. (2002) HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine 18: 231-6. Brandstetter, K.A., Jurcisek, J.A., Goodman, S.D., Bakaletz, L.O., and Das, S. (2013) Antibodies directed against integration host factor mediate biofilm clearance from Nasopore. Laryngoscope 123: 2626-32. Brockson, M.E. et al. (2014) Evaluation of the kinetics and mechanism of action of anti-integration host factor mediated disruption of bacterial biofilms. Mol Microbiol. Davalos, A.R. et al. (2013) p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol 201: 613-29. Devaraj, A., Justice, S.S., Bakaletz, L.O., and Goodman, S.D. (2015) DNABII proteins play a central role in UPEC biofilm structure. Mol Microbiol. Freire, M.O. et al. (2016) A Bacterial Biofilm Induced Oral Osteolytic Infection Can be Successfully Treated by Immuno-Targeting an Extracellular Nucleoid Associated Protein. Mol Oral Microbiol. Gong, W., Li, Y., Chao, F., Huang, G., and He, F. (2009) Amino acid residues 201-205 in C-terminal acidic tail region plays a crucial role in antibacterial activity of HMGB1. J Biomed Sci 16: 83. Goodman, S.D. et al. (2011) Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol 4: 625-37. Goodwin, G.H., Sanders, C., and Johns, E.W. (1973) A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 38: 14-9. Gustave, J.E., Jurcisek, J.A., McCoy, K.S., Goodman, S.D., and Bakaletz, L.O. (2013) Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis. J Cyst Fibros 12: 384-9. Idicula, W.A. et al. (2016) Identification of biofilms in post-tympanostomy tube otorrhea. Laryngoscope In Press. Justice, S.S. et al. (2012) Aberrant community architecture and attenuated persistence of uropathogenic Escherichia coli in the absence of individual IHF subunits. PLoS One 7: e48349. Kang, R. et al. (2014) HMGB1 in health and disease. Mol Aspects Med 40: 1-116. Kazama, H., Ricci, J.E., Herndon, J.M., Hoppe, G., Green, D.R., and Ferguson, T.A. (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29: 21-32. Lee, H. et al. (2010) Analysis of nuclear high mobility group box 1 (HMGB1)-binding proteins in colon cancer cells: clustering with proteins involved in secretion and extranuclear function. J Proteome Res 9: 4661-70. Mardente, S. et al. (2012) HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol Rep 28: 2285-9. Melloni, E., Sparatore, B., Patrone, M., Pessino, A., Passalacqua, M., and Pontremoli, S. (1995a) Extracellular release of the 'differentiation enhancing factor', a HMG1 protein type, is an early step in murine erythroleukemia cell differentiation. FEBS Lett 368: 466-70. Melloni, E., Sparatore, B., Patrone, M., Pessino, A., Passalacqua, M., and Pontremoli, S. (1995b) Identity in molecular structure between "differentiation enhancing factor" of murine erythroleukemia cells and the 30 kD heparin-binding protein of developing rat brain. Biochem Biophys Res Commun 210: 82-9. Novotny, L.A., Amer, A.O., Brockson, M.E., Goodman, S.D., and Bakaletz, L.O. (2013a) Structural stability of Burkholderia cenocepacia biofilms is reliant on eDNA structure and presence of a bacterial nucleic acid binding protein. PLoS One 8: e67629. Novotny, L.A., Clements, J.D., and Bakaletz, L.O. (2011) Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae. Mucosal Immunol 4: 456-67. Novotny, L.A., Clements, J.D., and Bakaletz, L.O. (2013b) Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization. Vaccine 31: 3417-26. Novotny, L.A., Jurcisek, J.A., Goodman, S.D., and Bakaletz, L.O. (2016) Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo. EBioMedicine 10: 33-44. Orlova, V.V. et al. (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26: 1129-39. Paull, T.T., Haykinson, M.J., and Johnson, R.C. (1993) The nonspecific DNA-binding and -bending proteins HMG1 and HMG2 promote the assembly of complex nucleoprotein structures. Genes Dev 7: 1521-34. Penzo, M. et al. (2010) Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol 184: 4497-509. Pistoia, V. and Raffaghello, L. (2011) Damage-associated molecular patterns (DAMPs) and mesenchymal stem cells: a matter of attraction and excitement. Eur J Immunol 41: 1828-31. Ranzato, E., Patrone, M., Pedrazzi, M., and Burlando, B. (2009) HMGb1 promotes scratch wound closure of HaCaT keratinocytes via ERK1 / 2 activation. Mol Cell Biochem 332: 199-205. Rocco, C.J., Davey, M.E., Bakaletz, L.O., and Goodman, S.D. (2016) Natural antigenic differences in the functionally equivalent extracellular DNABII proteins of bacterial biofilms provide a means for targeted biofilm therapeutics. Mol Oral Microbiol. Segall, A.M., Goodman, S.D., and Nash, H.A. (1994) Architectural elements in nucleoprotein complexes: interchangeability of specific and non-specific DNA binding proteins. EMBO J 13: 4536-48. Tang, D., Kang, R., Livesey, K.M., Zeh, H.J., 3rd, and Lotze, M.T. (2011) High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 15: 2185-95. Wang, H. et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-51. Yang, D., Chen, Q., Yang, H., Tracey, K.J., Bustin, M., and Oppenheim, J.J. (2007) High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 81: 59-66. Yang, H. et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 18: 250-9. Zetterstrom, C.K., Strand, M.L., and Soder, O. (2006) The high mobility group box chromosomal protein 1 is expressed in the human and rat testis where it may function as an antibacterial factor. Hum Reprod 21: 2801-9.
Claims
1. 1. A composition comprising an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain to inhibit or compete for binding of a deoxyribonucleic acid B II (DNABII) polypeptide to microbial DNA in a biofilm, comprising: The modified high mobility group-box 1 domain consists of the sequence of SEQ ID NO:2 having a C45S substitution or having a C23S and / or C106S substitution in addition to C45S; The composition is characterized in that it is contacted with the microbial DNA in the biofilm, thereby inhibiting or competing with binding of the DNABII polypeptide to the microbial DNA.
2. The composition of claim 1, wherein the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S.
3. The composition of claim 1 or 2, wherein the composition is contacted with the biofilm in vitro or in vivo.
4. The microbial DNA in the biofilm includes Burkholderia cenocepacia, Enterobacter spp.
4. The composition according to claim 1, wherein the composition is formed by a microorganism selected from the group consisting of Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), and Aggregatibacter actinomycetemcomitans.
5. The composition of any one of claims 1 to 4, wherein the biofilm is on a surface.
6. 1. An in vitro method for preventing the formation of a biofilm containing microbial DNA on a surface, comprising contacting the surface with an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain; The modified high mobility group-box 1 domain consists of the sequence of SEQ ID NO:2 having a C45S substitution or having a C23S and / or C106S substitution in addition to C45S.
7. The method of claim 6, wherein the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S.
8. The method of claim 6 or 7, wherein the surface is coated with the modified high mobility group-box 1 domain.
9. The microbial DNA in the biofilm includes Burkholderia cenocepacia, Enterobacter spp.
9. The method according to any one of claims 6 to 8, wherein the bacterial cell is formed by a microorganism selected from the group consisting of Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsular Haemophilus influenzae (NTHI), and Aggregatibacter actinomycetemcomitans.
10. The method of any one of claims 6 to 9, further comprising coating the surface with an effective amount of an antibiotic.
11. 1. A composition for preventing or treating a microbial infection in a biofilm-producing subject, comprising an effective amount of an isolated or recombinant polypeptide comprising a modified high mobility group-box 1 domain, The modified high mobility group-box 1 domain consists of the sequence of SEQ ID NO:2 having a C45S substitution or having a C23S and / or C106S substitution in addition to C45S; The composition is administered, thereby inhibiting or competing with binding of a DNABII polypeptide to microbial DNA.
12. The composition of claim 11, wherein the modified high mobility group-box 1 domain comprises the substitutions C23S, C45S, and C106S.
13. 13. The composition of claim 11 or 12, wherein the microbial infection is caused by Burkholderia cenocepacia, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterococcus faecium, uropathogenic Escherichia coli (UPEC), non-capsulated Haemophilus influenzae (NTHI), or Aggregatibacter actinomycetemcomitans.
14. The composition according to any one of claims 11 to 13, further comprising an effective amount of an antibiotic.
Citation Information
Patent Citations
Compositions and methods for removing biofilms
JP2013542185A
HMGB1 variants and uses thereof
WO2014016417A1
